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aa  amino acid  
Ang  angiopoietin 
AP-2  activator protein-2 
bHLH  basic helix-loop-helix 
ChIP  chromatin immunoprecipitation 
E  embryonic day 
EBS  Ets binding site 
EC  endothelial cell 
ECM  extracellular matrix 
EGFP  “enhanced” green fluorescent protein 
EGR-1  early growth response transcription factor 
Elk-1  Ets-like protein 1 
EMSA  electrophoretic mobility shift assay 
ENG  endoglin 
eNOS  endothelial nitric oxide synthase 
EPAS1  endothelial PAS domain protein 1 
Erf  Ets2 repressor protein 
Erg  transcription factor encoded by Ets-related gene 
ET-1  endothelin-1 
Ets  group of helix-loop helix transcription factors that contain an ETS DNA-binding domain 
FACS  fluorescence activated cell sorting 
Flk1  fetal liver kinase 1 (VEGFR-2) 
Flt1  fms-like tyrosine kinase 1 (VEGFR-1) 
Flt4  fms-like tyrosine kinase 4 (VEGFR-3) 
FOXC2  forkhead box C2 transcription factor 
GATA1-6 GATA transcription factors 1-6  
GFP  green fluorescent protein 
HBS  HIF binding site 
hGH  human growth hormone 
HIF  hypoxia-inducible factor 
hnRNA  heterogenous nuclear RNA 
HR  homology region 
HSPG  heparan sulfate proteoglycan 
ICAM  intercellular adhesion molecule  
Ig  immunoglobulin 
kbp  kilobasepair 
KDR  kinase insert domain containing receptor (VEGFR-2) 
LacZ  bacterial gene encoding for ß-galactosidase enzyme 
LKLF  lung Kruppel-like factor 
LLC  Lewis lung carcinoma 
LYVE-1  lymphatic vessel endothelial hyaluronan receptor-1 
MAPK  mitogen-activated protein kinase 
MEF-2  myocyte enhancer factor 2 
MMP  matrix metalloproteinase 
mRNA  messenger RNA 
Net  new Ets transcription factor 
Oct1  ubiquitous octamer-binding protein 
P  postnatal day 
PAS  Per/Arnt/Sim 
PCR  polymerase chain reaction 
PDGF  platelet-derived growth factor 
PDGFR  PDGF receptor 
PECAM  platelet-endothelial cell adhesion molecule 
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NERF  new ets related factor  
NF-1  nuclear factor-1 
PI3K  phosphatidylinositol 3´-kinase 
PlGF  placenta growth factor 
PMA  phorbol 12-myristate 13-acetate 
Prox-1  prospero-related homeobox protein 1 
RTK  receptor tyrosine kinase 
SAP-1  serum response factor accessory protein 1 
Scl/Tal  Stem cell leukemia/T-cell acute leukemia 
SLC  secondary lymphoid organ chemokine 
SMC  smooth muscle cell 
Sp1  specificity protein 1, transcription factor which binds to GC box element 
Tek  tunica interna endothelial cell kinase (Tie2) 
TGF  transforming growth factor 
Tie  tyrosine kinase with immunoglobulin and epidermal growth factor homology domains 
TNFα tumor necrosis factor-α 
VE-cadherin vascular endothelial-cadherin 
VEGF  vascular endothelial growth factor 
VEGFR  VEGF receptor 
Vezf1  vascular endothelial zinc finger 1 
vWF  von Willebrand factor 
WT   wild type 
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Endothelial cells lining the blood and 
lymphatic vessels are dependent on re-
ceptor tyrosine kinase mediated signal-
ing, which leads to growth or differentia-
tion responses in the target cells. The 
endothelial-specific receptor tyrosine 
kinases can be grouped into two sub-
families: Tie (tyrosine kinase with im-
munoglobulin and epidermal growth fac-
tor like domains) and VEGF (vascular 
endothelial growth factor) receptors. The 
Tie family consists of two members, 
Tie1 and Tie2, whereas three VEGF re-
ceptors, VEGFR-1, -2, and -3 have been 
identified. All of these receptors are vital 
for the normal development of the blood 
vasculature.  
 
This study was undertaken to investigate 
the transcriptional regulation of Tie1 and 
Vegfr3 genes. The Tie1 promoter region 
that targets expression of the LacZ 
marker gene specifically to endothelial 
cells in transgenic mice had been previ-
ously identified. We studied Tie1 pro-
moter activity further and showed that 
the binding sites for Ets transcription 
factors are important for its activity. In 
addition, we demonstrated that several 
Ets factors transactivate Tie1 promoter, 
among which NERF-2 showed the 
strongest transactivation. Furthermore, 
we found that the Tie1 promoter directs 
the production of high amounts of hu-
man growth hormone into the circulation 
in transgenic mice, indicating that it has 
potential for use in vectors for endothe-
lial cell-specific gene expression. 
 
To allow intravital monitoring of the 
vascular development and isolation of 
primary mouse endothelial cells, we 
generated fluorescent Tie1 reporter mice. 
Although Tie1 has been used as a uni-
versal marker for blood vascular endo-
thelium, our analysis of Tie1 promoter 
activity in various reporter mice revealed 
a significant degree of specificity in dif-
ferent types of endothelial cells. Starting 
at midgestation, Tie1 promoter activity 
became stronger in the arterial than in 
the venous endothelium. Surprisingly, 
Tie1 promoter activity was detected also 
in the lymphatic vessels. Furthermore, 
by using a transplantable tumor model, 
we showed that the regulatory elements 
needed for Tie1 expression in tumor ne-
ovasculature are not present within the 
0.8 kbp mouse Tie1 promoter, indicating 
the presence of additional regulatory 
elements in the Tie1 locus.  
 
To identify regulatory elements impor-
tant for lymphatic transcription, we 
characterized the 5´ flanking regions of 
human and mouse VEGFR3 genes. Al-
though Vegfr3 gene expression is neces-
sary for vascular development, it be-
comes gradually more restricted to the 
lymphatic endothelium during embryo-
genesis. Critical regulatory elements for 
lymphatic endothelial cell specific activ-
ity of the Vegfr3 promoter in vivo were 
found to reside in a 1.6 kbp fragment 
upstream of the translational initiation 
codon. This promoter fragment contains 
two conserved regions having putative 
binding motifs for transcription factors 
belonging to MEF-2, NF-1, AP-2, 
GATA, Ets and Sp1 families. Further 
studies are needed to determine which of 
these binding sites are critical for the 
Vegfr3 promoter activity and whether 
additional enhancer elements exist that 
are responsible for strong promoter ac-
tivity in the lymphatic endothelium.  
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REVIEW OF THE LITERATURE 
1 ENDOTHELIAL RECEPTOR TYROSINE KINASES AND VASCULAR 
DEVELOPMENT 
1.1 Molecular structure of endothelial receptor tyrosine kinases and their ligands 
Endothelial cells (ECs) lining the blood 
and lymphatic vessels are dependent on 
receptor tyrosine kinase (RTK) mediated 
signaling, which leads to growth or dif-
ferentiation responses in the target cells. 
This signaling is required for normal de-
velopment and maintenance of the vas-
cular bed as well as for angiogenic re-
sponses in pathological conditions. 
RTKs are classified into subclasses 
based on sequence similarities and dis-
tinct structural characteristics. They con-
tain a ligand binding extracellular part, a 
single membrane spanning region, and a 
cytosolic domain for signal transduction. 
A juxtamembrane region is located on 
the cytoplasmic side and it is followed 
by the conserved kinase domain. RTKs 
dimerize in response to the binding of 
specific ligands. Dimerization is fol-
lowed by transphosphorylation of the 
tyrosine residues in the activation loop 
(Hubbard et al., 1998; Schlessinger, 
2000). The phosphorylated tyrosine resi-
dues outside the catalytic domain act as 
specific docking sites for intracellular 
signaling proteins containing Src homol-
ogy 2 (SH2) and phosphotyrosine-
binding (PTB) domains, promoting the 
assembly of intracellular signaling com-
plexes (Schlessinger, 2000). The recep-
tor mediated activation of intracellular 
signaling cascades usually targets tran-
scription factors, modifies their activity 
and reprograms gene expression.  
 
Vascular endothelial cells express non-
lineage restricted RTKs such as recep-
tors for fibroblast growth factors, epi-
dermal growth factors, and hepatocyte 
growth factor, but also endothelial cell-
restricted RTKs. Two major families of 
endothelial RTKs consist of Tie (tyro-
sine kinase with immunoglobulin and 
epidermal growth factor like domains) 
and VEGF (vascular endothelial growth 
factor) receptors (Fig. 1).  
 
Two members of the Tie receptor fam-
ily, Tie1 and Tie2, have been identified, 
as well as four Tie2 ligands, called an-
giopoietins (Angs) 1-4 (Davis et al., 
1996; Dumont et al., 1992; Maisonpierre 
et al., 1997; Partanen et al., 1992; 
Valenzuela et al., 1999). Although Tie1 
was discovered more than ten years ago, 
no ligand for this receptor has been 
found. Tie receptors have two immu-
noglobulin (Ig) homology domains, 
three fibronectin type III homology do-
mains and three epidermal growth factor 
homology domains in their extracellular 
region, followed by a hydrophobic 
transmembrane domain and an intracel-
lular tyrosine kinase domain interrupted 
by a small stretch of amino acids com-
monly referred to as the kinase insert. 
Ang1 and Ang4 induce the phosphoryla-
tion of Tie2, Ang3 acts as an antagonist 
and the effect of Ang2 is context de-
pendent, either antagonistic or agonistic 
for the activation of  Tie2 (Davis et al., 
1996; Maisonpierre et al., 1997; 
Valenzuela et al., 1999). The structure of 
angiopoietins can be divided into N-
terminal coiled-coil domains and car-
boxy-terminal fibrinogen-like domains, 
separated by a linker region. The coiled-
coil segment is thought to promote mul-
timerization of the ligand chains. Ang2 
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appears to exist predominantly as 
homodimers but it is also capable of 
forming higher order multimers whereas 
Ang1 exists predominantly as higher or-
der multimers (Procopio et al., 1999; 
Davis et al., 2003). The linker region of 
Ang1 is responsible for its binding to the 
extracellular matrix (ECM) whereas 
Ang2 does not bind to the ECM. The 
fibrinogen-like domain represents the 
most conserved region of the angiopoi-
etins and is critical for receptor-binding 





Figure 1. Endothelial cell tyrosine kinase receptors and their ligands. These structurally divergent re-
ceptors are subgrouped into the Tie and VEGF receptor (VEGFR) families. Binding specificities of Tie 
receptor ligands (Ang1-4) and VEGF receptor ligands (VEGF-A to -E and PlGF) are indicated in the fig-
ure. Structural motifs present within the receptor families are indicated. Ig, immunoglobulin-like domain; 
EGF, epidermal growth factor domain; FNIII, fibronectin type III homology domain, KD, kinase domain. 






The VEGF receptor family consists of 
three members, VEGFR-1, -2 and -3, 
originally named flt1 (fms-like tyrosine 
kinase-1), KDR (kinase insert domain 
containing receptor)/FLK-1 (fetal liver 
kinase-1) and Flt4, respectively. The ex-
tracellular regions of VEGFR-1 and 
VEGFR-2 contain seven Ig domains that 
are stabilized by disulphide links be-
tween paired cysteine residues. In 
VEGFR-3, the fifth Ig domain is prote-
olytically cleaved and the resulting 
polypeptides remain linked by two disul-
fide bonds (Lee et al., 1996; Pajusola et 
al., 1993; Pajusola et al., 1992) (Fig. 1). 
As in Tie receptors, the kinase domain in 
VEGFRs is split by a kinase insert. Sev-
eral splice variants have been identified 
for genes encoding VEGFR-1 and 
VEGFR-3. In addition to the transmem-
brane VEGFR-1 splice form, an alterna-
tively spliced form differing in the 
COOH terminal region, and a soluble 
splice variant, lacking sequences encod-
ing for the seventh immunoglobulin-like 
domain as well as transmembrane and 
intracellular domains, have been charac-
terized (De Vries et al., 1992; Kendall 
and Thomas, 1993; Shibuya et al., 
1990). In humans, a shorter VEGFR-3 
transcript, resulting from alternative 3´ 
polyadenylation signals and lacking the 
codons for 65 amino acid residues pre-
sent in the major form has been charac-
terized (Hughes, 2001).   
 
Six growth factors (VEGF-A to -E and 
PlGF) binding to VEGFRs have been 
identified. There are several VEGF 
(VEGF-A) protein isoforms in mouse 
(120, 164, 188) and in human (121, 145, 
165, 183, 189 and 206 aa). All the 
VEGF isoforms bind to VEGFR-1 and 
VEGFR-2. VEGF binds to its receptors 
as a dimer. VEGF may also form het-
erodimers with VEGF-B and PlGF (pla-
centa growth factor). VEGF-B and PlGF 
bind only VEGFR-1 whereas VEGF-C 
and VEGF-D can interact with both 
VEGFR-2 and VEGFR-3. VEGF-C and 
VEGF-D are expressed as preproproteins 
which are proteolytically processed into 
polypeptides with increasing affinity to-
wards VEGFR-3, and only the fully 
processed forms can bind to and activate 
VEGFR-2 (Joukov et al., 1997; Stacker 
et al., 1999). However, although human 
VEGF-D is a ligand for both VEGFR-2 
and VEGFR-3, mouse VEGF-D binds 
selectively to VEGFR-3 (Baldwin et al., 
2001). Viral VEGF-like polypeptides are 
commonly named as VEGF-E, and bind 
to VEGFR-2 (Wise et al., 1999). In addi-
tion to the VEGFRs, certain splice iso-
forms of VEGF, PlGF, VEGF-B, VEGF-
C and VEGF-E also bind the sema-
phorin/collapsin receptors called neu-
ropilins 1 and 2, as well as heparan sul-
fate proteoglycans (HSPGs) on the cell 
surface and in the pericellular matrix 
(Gluzman-Poltorak et al., 2000; Kark-
kainen et al., 2001; Migdal et al., 1998; 
Mäkinen et al., 1999; Soker et al., 1998; 
Wise et al., 1999). 
 
1.2  Cardiovascular system
The cardiovascular system consists of 
the heart, blood vessels (arteries, veins 
and capillaries) and lymphatic vessels 
(Fig. 2). The heart pumps oxygenated 
blood via arteries to the capillaries where 
bidirectional exchange of gases and me-
tabolites occurs between blood and tis-
sues. Veins collect deoxygenated blood 
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from the microvasculature and transport 
it back to the heart. Due to the high pres-
sure in the circulatory system, fluid leaks 
out from the blood capillaries. Most of 
this extravasated tissue fluid is reab-
sorbed at the venous end of capillaries 
and postcapillary venules. However, this 
reabsorption is not sufficient for main-
taining body fluid balance, and another 
system, the lymphatic system, is needed 
to collect the remaining extravasated tis-
sue fluid. Lymphatic vessels return fluid 
back to the blood circulation through the 
thoracic and lymphatic ducts and the 
lymphaticovenous anastomoses.  
 
 
The formation of a functional vascular 
system is the result of a complex series 
of coordinated processes between differ-
ent cell types and the ECM. The princi-
pal cell types involved in the develop-
ment of the vascular system are ECs and 
periendothelial support cells, including 
vascular smooth muscle cells (SMCs) 
and pericytes. ECs cover the entire inner 
surface of blood and lymphatic vessels 
and form the endocardium, the inner lin-
ing of the cardiac lumen. During vascu-
lar development, endothelial tubes form 
first and then acquire the mural cell coat-
ing. The ECM between endothelial and 
periendothelial cells has both structural 




Figure 2. A schematic presentation of the cardiovascular system. (A) Heart, blood vessels and lym-
phatic vessels form the cardiovascular system. Oxygenated blood is transported via arteries to the capillar-
ies, where bidirectional exchange occurs between blood and tissues. Veins collect deoxygenated blood and 
carry it back to the heart. Lymphatic vessels collect extravasated tissue fluid, filter it through lymph nodes 
and return it back to the blood circulation. (B) Blood vessels have a continuous basal lamina with tight in-
terendothelial junctions and they are supported by periendothelial support cells. In contrast, lymphatic ves-
sels have a discontinuous basal lamina and have gaps between the lymphatic ECs. Anchoring filaments 
attach lymphatic vessels to the surrounding tissue. Bileaflet valves prevent backflow of lymphatic fluid. 
Adapted from Jones et al., 2001. 
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1.2.1 Blood vascular system 
Development of the blood vessels 
Cardiovascular system is the first func-
tional organ system to form in order to 
supply the nutritional requirements of 
the developing embryo. In humans, de-
velopment of the circulatory system 
starts already in the third week of em-
bryonic life. Accordingly, VEGFs and 
their receptors are expressed early in 
embryonic development. Results from 
mRNA in situ hybridizations indicate 
that VEGF and VEGFR-2 expression 
start in mouse yolk sac and in the em-
bryo proper at embryonic day (E) 7. 
VEGFR-1 expression starts a bit later, at 
E7.5 in the amnion and at E9.5 in the 
embryonic mesoderm. Northern blotting 
results indicate that VEGF-C expression 
starts at E7 and by in situ hybridization, 
first VEGFR-3 mRNA expression was 
detected at E8.5. All VEGFRs have dis-
tinct, though partly overlapping expres-
sion profiles, suggesting that these RTKs 
play unique functions in vascularization 
of the embryo (Kaipainen et al., 1993; 
Partanen et al., 1999b). Tie1 and Tie2 
mRNAs are first expressed around E8 
(Dumont et al., 1995; Dumont et al., 
1992; Korhonen et al., 1994). In addition 
to these EC specific receptors, some 
members of the large Eph RTK family 
are expressed in ECs and participate in 
blood vessel development. The signifi-
cance of signaling via these RTKs to 
vascular development has been demon-
strated using gene-targeted animals. The 
main processes of vascular development 
and the molecular mechanisms regulat-
ing these events are summarized below 
and in Table 1. 
Vasculogenesis 
Hemangioblasts, the progenitor cells of 
both blood and endothelial cells, differ-
entiate from the embryonic mesoderm. 
Endothelial progenitor cells are called 
angioblasts. The formation of blood ves-
sels from in situ differentiating an-
gioblasts is called vasculogenesis. In the 
yolk sac, angioblasts and hematopoietic 
precursor cells are formed in close asso-
ciation, in so-called blood islands, which 
are aggregates of hemangioblasts. The 
inner cells differentiate into hematopoi-
etic precursors and the outer cells into 
endothelial cells (Fig. 3). Primordial 
vascular network is formed when blood 
islands fuse and a lumen is formed by 
angioblasts (Risau and Flamme, 1995). 
As a result of subsequent EC prolifera-
tion, migration and organization, a pri-
mary capillary plexus consisting of ho-
mogenously sized endothelial tubes is 
formed. In the embryo, except for a 
small region in the aorta, ECs differenti-
ate from the mesoderm as angioblasts, 
without paralell differentiation of the 
hematopoietic cells. Intraembryonic he-
matopoietic precursors localized in the 
aorta bud serve as founders of lineages 
of definitive hematopoiesis which occurs 
sequentially in several organs, including 
the liver, spleen and bone marrow. The 
primitive vasculature of endodermally 
derived organs such as lung, liver, and 
spleen, heart endocardium and paired 
dorsal aortas are formed by vascu-
logenesis. 
 
The molecular mechanisms behind the 
differentiation of embryonic mesoderm 
in mouse and in human are still poorly 
understood. VEGFR-2 is the first mole-
cule known to be expressed in an-
gioblasts and the onset of VEGFR-2 ex-
pression in mesodermal precursor cells 
is thought to mark the establishment of 
the hemangioblastic lineage during em-
bryonic development (Yamaguchi et al., 
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1993). Whereas blood islands differenti-
ate spontaneously in a mouse model us-
ing embryonic stem cell-derived cystic 
embryoid bodies, fibroblast growth fac-
tors are important for the differentiation 
of ECs in amphibian and avian models 
(Flamme et al., 1997; Flamme and Ri-
sau, 1992; Mitrani et al., 1990). VEGF 
secreted by the endoderm may support 
the differentiation of VEGFR-2 express-
ing mesodermal cells to angioblasts. Re-
sults from knockout studies in mice have 
proven that VEGF and VEGFR-2 are 
absolutely critical for the earliest stages 
of vasculogenesis in vivo, as blood is-
lands, endothelial cells and major vessel 
tubes fail to develop in appreciable 
numbers in embryos lacking either 
VEGF or VEGFR-2 (Carmeliet et al., 
1996; Ferrara et al., 1996; Shalaby et al., 
1997; Shalaby et al., 1995). On the con-
trary, VEGFR-1 seems to inhibit heman-
gioblast commitment, as the null em-
bryos generate too many endothelial 
cells entering into the lumens of the ab-
normal vascular channels, leading to 
embryonic death at E8.5 (Fong et al., 
1999; Fong et al., 1995).  
Table 1. Summary of knockout studies of ligands and receptors regulating vasculogenesis and angio-
genesis. See the text for references. 
Gene  Null phenotype Lethal at Functions 
VEGF Defective EC development E8-9 (-/-) 
E11-12 (+/-) 
Induction of ECs, vasculogenesis, 
angiogenesis 
PIGF Impaired pathological angiogene-
sis 
Survive Recruitment of endothelial progenitor 
cells? 
VEGF-B Heart defects, impaired patho-
logical angiogenesis 
Survive Modulation  of VEGF activity (?) 
VEGFR-1 Excess ECs, abnormal vessel 
structures 
E8.5 Modulation of VEGFR-2 activity, 
pathological angiogenesis 
VEGFR-2 Lack of endothelial and hemato-
poietic cells  
E8.5-9.5 Hemangioblast migration, differentia-
tion, proliferation 
VEGFR-3 Defective vascular remodelling  E9.5-10.5 Blood vessel maturation, lymphatic 
vessel development and function 
Ang-1 Impaired endocardial develop-
ment and myocardial trabecula-
tion, lack of pericytes 
E12.5 Blood vessel stabilisation 
Ang-2 Defective postnatal vascular re-
modelling, lymphatic drainage 
problems 
<P14 Blood vessel destabilisation, lym-
phatic vessel development and func-
tion 
Tie-1 Poor endothelial integrity, edema, 
and hemorrhage 
E13.5-P0 EC-pericyte interactions 
Tie-2 Heart trabeculation defects, de-
creased EC survinal and sprout-
ing, hemorrhages 
E9.5-10.5 EC-pericyte interactions 
PDGF-Β Hemorrhage, loss of perivascular 
cells 
P0 Pericyte recruitment 
PDGF-Rβ Hemorrhage, loss of perivascular 
cells 
P0 Pericyte maturation, blood vessel 
stabilisation 
Ephrin-B2 Defective vascular remodelling, 
organization and sprouting 
E10.5 Establishment of arterial EC identity 




During the subsequent process of angio-
genesis, ECs proliferate and sprout from 
pre-existing vascular network (Fig. 3). 
The primary capillary network is remod-
eled until a mature vasculature consist-
ing of vessels of different diameters and 
functions is formed. This remodeling 
occurs by regression, sprouting, splitting 
or fusion of pre-existing vessels (Risau, 
1997). During embryogenesis, most or-
gans are vascularized by a combination 
of vasculogenesis and angiogenesis. 
However, some ectodermal tissues, such 
as the brain, become vascularized exclu-




Figure 3. Embryonic blood vessel development. In vasculogenesis, endothelial cell precursors, an-
gioblasts, differentiate in the yolk sac and in the embryo. Primordial vascular network is formed by fusion 
of the angioblasts. In angiogenesis, the primary capillary plexus is remodeled by regression and expansion 
of primitive vessels to form mature blood vessels, some of which are covered by periendothelial support 
cells. Adapted from Carmeliet, 2000. 
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Our understanding of the molecular 
players involved in angiogenesis has in-
creased enormously during the last dec-
ade. In addition to its fundamental role 
in vasculogenesis, VEGF is the major 
regulator in angiogenesis. VEGF expres-
sion levels are tightly regulated during 
development, as even the loss of a single 
VEGF allele results in embryonic lethal-
ity at E11-12 (Carmeliet et al., 1996; 
Ferrara et al., 1996). A variety of growth 
factors and cytokines including epider-
mal growth factor, basic fibroblast 
growth factor (bFGF), transforming 
growth factor-ß (TGF-ß), and keratino-
cyte growth factor-1 induce the tran-
scription of VEGF mRNA (Ferrara, 
1999). It is possible that these growth 
factors mediate the developmental regu-
lation of VEGF. Also a lack of oxygen, 
hypoxia, is one of the major regulators 
of VEGF, inducing rapid and reversible 
VEGF expression by increasing its tran-
scription and mRNA stabilization (Levy 
et al., 1996; Levy et al., 1995; Plate et 
al., 1992; Shweiki et al., 1992). Hy-
poxia-induced transcription of VEGF 
mRNA is mediated by hypoxia-inducible 
factor-1 (HIF-1) (Semenza, 1996).  Hy-
poxia leads to stabilization of HIF-1 pro-
tein that is extremely labile in normoxic 
conditions, and it plays a role at least in 
some vascularization processes such as 
formation of the retina vasculature 
(Huang et al., 1996; Stone et al., 1995).  
 
Recently, isoform-specific knock-outs of 
the VEGF gene have been generated. 
While mice expressing only the 164 aa 
isoform of VEGF are normal, those ex-
pressing only 120 or 188 aa isoforms 
display various defects (Carmeliet et al., 
1999b; Maes et al., 2002; Stalmans et 
al., 2002). Mice expressing only the 120 
aa isoform of VEGF have defects in the 
heart, bone formation and retinal angio-
genesis, whereas mice expressing only 
VEGF188 have impaired arteriolar de-
velopment (Carmeliet et al., 1999b; 
Maes et al., 2002; Stalmans et al., 2002). 
These results indicate that not all VEGF 
isoforms can completely replace the 
function of the others. 
 
VEGF induces permeability, prolifera-
tion, migration, survival, sprouting and 
tube formation in cultured ECs (Ferrara, 
1999). These responses are largely me-
diated by the VEGFR-2 receptor, al-
though the binding affinity of VEGF for 
VEGFR-2 is lower than for VEGFR-1 
(De Vries et al., 1992; Terman et al., 
1992). VEGFR-1 has probably a modify-
ing function, mostly by acting as a decoy 
receptor, as mutant mice expressing 
VEGFR-1 lacking its tyrosine kinase 
domain have normal vascular develop-
ment (Hiratsuka et al., 1998). Also 
VEGF-E, which does not bind to 
VEGFR-1, is able to carry out most of 
the functions that VEGF does in vitro, 
indicating that VEGFR-2 is the major 
receptor that conveys VEGF-induced 
signals in endothelial cells (Meyer et al., 
1999; Wise et al., 1999). However, 
VEGFR-1 signaling is required for op-
timal monocyte and trophoblast function 
(Clauss et al., 1996; Desai et al., 1999). 
 
VEGFR-2 works in conjunction with 
several adhesion receptors including 
vascular endothelial (VE)-cadherin and 
integrins during angiogenesis. Both the 
targeted deficiency and the cytosolic 
truncation of VE-cadherin in mice re-
sulted in the same kind of vascular de-
fects and embryonic lethality at E9.5 
(Carmeliet et al., 1999a). The defects 
were observed in VEGF-mediated an-
giogenesis and EC survival. VEGF in-
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duces tyrosine phosphorylation of VE-
cadherin (Esser et al., 1998). Studies in 
cultured cells indicate that VE-cadherin 
plays a role in VEGF-mediated EC sur-
vival through VEGFR-2 (Carmeliet et 
al., 1999a). The exact nature of VEGFR-
2 and integrin co-signaling is unknown, 
but it has been speculated that integrins 
may enhance the clustering and dimeri-
zation of VEGFR-2 subunits in response 
to VEGF, thereby enhancing the 
VEGFR-2 signaling (Tallquist et al., 
1999).  
 
In addition to VEGFR-1 and -2, 
VEGFR-3 is essential for normal devel-
opment of the blood vasculature, as tar-
geted inactivation of the VEGFR-3 gene 
in mice leads to defective remodeling of 
the primary vascular plexus, disturbed 
hematopoiesis and cardiovascular failure 
resulting in embryonic lethality at E9.5 
(Dumont et al., 1998; Hamada et al., 
2000). The exact roles of VEGF-C and 
VEGF-D during embryonic vascular de-
velopment are still unknown due to lack 
of gene deletion studies. However, when 
VEGF-C was applied to the early 
chorioallantoic membrane (CAM), 
where lymphatics have not yet devel-
oped, it promoted angiogenesis, whereas 
in mature CAM it promoted lymphan-
giogenesis (Oh et al., 1997). The angio-
genic vs. lymphangiogenic role of 
VEGF-C may depend on the degree of 
proteolytic processing of its precursor 
and on the expression of its receptors. 
Recent data from several transgenic 
mouse studies suggest that VEGFR-3 
and VEGF-C play a major role in lym-
phangiogenesis (see section: Develop-
ment of the lymphatic vessels). 
 
In contrast to the early defects in blood 
vessel formation in mice deficient of 
VEGF or its receptors, embryos lacking 
Tie receptors, Ang1 or Ang2 exhibit de-
fects somewhat later in angiogenesis. 
Although the early stages of vascular 
development appear to occur rather 
normally, mice deficient of Tie1 die be-
tween E13.5 and birth due to compro-
mised EC integrity leading to hemor-
rhages and abdominal edema (Puri et al., 
1995; Sato et al., 1995). Embryos lack-
ing Tie2 show an earlier lethal pheno-
type and die between E9.5 and E10.5 as 
a consequence of insufficient expansion 
and maintenance of the primary capillary 
plexus, failure of endothelial lining on 
the heart to develop properly and lack of 
capillary sprouts from the neuroecto-
derm (Dumont et al., 1994; Sato et al., 
1995). Interestingly, double null mouse 
embryos for the Tie1 and Tie2 receptors 
have a more severe phenotype compared 
to single knockout phenotypes, suggest-
ing that these receptors do biologically 
interact (Puri et al., 1999). It has been 
suggested that Tie1 modulates angiopoi-
etin signals via Tie2 (Maisonpierre et al., 
1997). Recently Tie1 and Tie2 receptor 
heterodimers have been shown to exist 
in cultured ECs, but Tie1 is not tran-
sphosphorylated on Tie2 receptor activa-
tion and the cellular function of het-
erodimerization remains to be deter-
mined (Marron et al., 2000).  
 
Ang1, the Tie2 agonistic ligand, is ex-
pressed most prominently in the heart 
myocardium at early stages of develop-
ment (E9-11) (Maisonpierre et al., 
1997). Later, it becomes more widely 
distributed in the mesenchyme surround-
ing developing vessels. Mice deficient of 
Ang1 die at E12.5 due to similar angio-
genic defects as seen in Tie2 knockout 
mice (Suri et al., 1996). As in Tie2 defi-
cient embryos, embryos lacking Ang1 
have defects in trabecular formation of 
the heart and show a less complex vas-
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cular network in general (Suri et al., 
1996). Also, as transgenic mice overex-
pressing Ang1 show hypervasculariza-
tion, activation of the Tie2 signaling 
pathway is definitely involved in vascu-
lar network formation (Suri et al., 1998). 
Ang2, the putative antagonistic ligand of 
Tie2, has a more punctate expression 
pattern than Ang1.  During the early em-
bryogenesis, Ang2 is expressed in the 
dorsal aorta and major aortic branches. 
Transgenic overexpression of Ang2 in 
the developing endothelium proved that 
Ang2 can act as a negative regulator of 
Tie2 as the mice had a phenotype remi-
niscent of that seen in embryos lacking 
either Ang1 or Tie2 leading to embry-
onic death at E9.5-10.5 (Hanahan, 1997; 
Maisonpierre et al., 1997).  
Vascular maturation 
Stabilization of the vasculature occurs 
when periendothelial support cells such 
as SMCs and pericytes are recruited to 
the vessel wall and the surrounding 
ECM is reconstituted (Fig. 3). Large ar-
teries, in which ECs are covered by a 
thick layer of SMCs, progressively 
branch into smaller vessels, terminating 
in precapillary arterioles. Arterioles are 
connected to capillaries, which are com-
prised almost entirely of ECs, with only 
occasional pericytes. Capillaries are 
connected to postcapillary venules that 
progressively associate into larger veins. 
Veins are fully enveloped by SMCs, al-
though not to the same extent as arteries.  
 
Vascular maturation is a critical step in 
blood vessel development, as in the ab-
sence of support cell coverage vessels 
undergo regression (Alon et al., 1995). 
VEGF accelerates the formation of peri-
cyte coverage, although the mechanism 
remains unknown (Benjamin et al., 
1998). Results from several studies indi-
cate that Tie receptors are involved in 
the regulation of EC-pericyte/SMC in-
teractions. A mutation in TIE2 locus has 
been identified in some families with 
inherited venous malformations 
(Vikkula et al., 1996). This mutation 
(R849W) increases the activity of TIE2 
tyrosine kinase, leading to enlarged vas-
cular channels with a relative lack of 
SMCs. The pericyte number is decreased 
also in the vasculature of Tie2 or Ang1 
deficient embryos (Patan et al., 1998; 
Suri et al., 1996). Ultrastructural exami-
nation of vessels in mice lacking Ang1 
showed that ECs are poorly associated 
with the underlying matrix and do not 
properly recruit and associate with 
periendothelial supporting cells (Suri et 
al., 1996). Consistently, overexpression 
of Ang1 in the skin results in the forma-
tion of leakage-resistant vessels, indicat-
ing that Ang1 inhibits vascular perme-
ability and stabilizes the existing vessels 
(Thurston et al., 2000; Thurston et al., 
1999). In Tie1-deficient embryos, the 
pericyte numbers are increased, while 
platelet-derived growth factor (PDGF)-B 
deficient embryos, which show upregu-
lated Tie1 expression, lack microvascu-
lar pericytes (Lindahl et al., 1997; Patan, 
1998). PDGF-B is the ligand for RTKs 
PDGFR-α and -ß (Heldin et al., 1998). It 
is expressed in ECs and it promotes pro-
liferation and migration of mesenchymal 
cells expressing the receptors. Targeted 
disruption of PDGF-B or PDGFR-ß 
genes in mice leads to hemorrhages and 
edema in late embryogenesis, demon-
strating the vital role of periendothelial 
cells for the development of functional 
vasculature (Levéen et al., 1994; Lindahl 
et al., 1997; Soriano, 1994). Also the 
ECM between ECs and pericytes has an 
important function in vascular develop-
ment as defects in the proper formation 
of the ECM lead to decreased pericyte 
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adhesion, migration and vessel stability 
(Beltramo et al., 2002; Thyboll et al., 
2002). During subsequent arteriogenesis, 
some vessels become covered by a mus-
cular coat, needed for viscoelastic and 
vasomotor functions. 
Heterogeneity of the vascular endothe-
lium 
Vascular endothelium is not a uniform, 
semipermeable layer. Instead, it is a dy-
namic entity, capable of functional and 
morphological adaptations in response to 
environmental requirements. Based on 
current knowledge, the diversity of ECs 
is generated by both endogenous altera-
tions and by exogenous stimuli from sur-
rounding tissues. 
 
On the basis of morphology, microvas-
cular endothelium has been divided into 
different phenotypes: continuous, fenes-
trated and discontinuous (Pasqualini et 
al., 2002). Capillaries in the skeletal 
muscle, heart, lung and brain are con-
tinuous. In these capillaries, the endothe-
lial cytoplasm is continuous and there is 
no fusion of luminal and abluminal 
plasma membranes except at the cell 
junctions. Fenestrated and discontinuous 
capillaries have pores and gaps between 
ECs. Capillaries in many endocrine and 
exocrine glands, choroid plexus and in-
testinal villi have fenestrations. Func-
tionally, fenestrated capillaries are more 
permeable than the continuous capillar-
ies, which is consistent with their pres-
ence at sites of filtration, secretion and 
absorption. Capillaries in the liver, 
spleen and bone marrow have discon-
tinuous endothelium with total or partial 
absence of basal lamina. Also the capil-
laries in different organs may be further 
specialized. This is the case for example 
in the brain, where capillaries form the 
blood-brain barrier. These capillaries 
have complex tight junctions between 
the ECs, which are primarily responsible 
for the barrier function needed to guar-
antee brain homeostasis. Because brain 
ECs are derived from external ECs by 
angiogenesis, the brain environment 
probably induces blood-brain barrier dif-
ferentiation in the invading ECs. Indeed, 
astroglial cells are able to induce at least 
some characteristics of the blood-brain 
barrier phenotype in ECs (Rubin and 
Staddon, 1999). Also endocardium can 
be considered a distinct type of endothe-
lium as it transdifferentiates to mesen-
chyme during formation of the cardial 
cushions (Sinning et al., 1992). 
 
Heterogeneity is evident also in large 
vessel endothelium, for example be-
tween arteries and veins. In addition to 
differences in structure and function, 
several genes are known to be differen-
tially expressed between the developing 
arteries and veins. These include the Eph 
family transmembrane ligand ephrin-B2, 
which is expressed only in the arteries 
and its receptor, EphB4, which is ex-
pressed only in veins (Wang et al., 
1998). In fact, the differential expression 
pattern between ephrin-B2 and EphB4 is 
seen in the developing vessels already 
before the onset of circulation, indicating 
that arteries and veins are genetically 
determined. Embryos lacking ephrin-B2 
or EphB4 display severe vascular defects 
including aberrant vessel remodeling and 
heart development, leading to embryonic 
death (Adams et al., 1999; Gerety et al., 
1999; Wang et al., 1998). Defects are 
seen in both arteries and veins, indicat-
ing that bidirectional signaling needed 
for normal vascular development occurs 
between ephrin-B2 and EphB4 (Gerety 
et al., 1999; Wang et al., 1998).  
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Little is known about the upstream fac-
tors responsible for defining the differ-
ences between arteries and veins. The 
activin receptor like kinase-1 (ACVRL1) 
participates in the determination of arter-
ies and veins, as a loss of function muta-
tion in ACVRL1 causes arteriovenous 
malformations (Johnson et al., 1996; 
Urness et al., 2000). Mice lacking 
Acvrl1 fail to express ephrin-B2 in their 
arterial vessels, suggesting a possible 
role for TGF-ß signaling during this 
process (Urness et al., 2000). In addi-
tion, Notch and gridlock pathways regu-
late the determination of arterial or ve-
nous endothelial cell fate (Lawson et al., 
2001; Zhong et al., 2001). Results from 
zebrafish studies indicate that an-
gioblasts of the lateral mesoderm are al-
ready restricted to an arterial or venous 
lineage (Zhong et al., 2001). Lack of ei-
ther Notch or gridlock (grl) expression 
leads to a failure to induce ephrin-B2 
and to enhanced expression of venous 
markers, indicating that these signaling 
pathways are needed for repression of 
the venous fate in order for the arterial 
fate to emerge. Recent data suggest that 
sonic hedgehog (Shh) acts upstream of 
VEGF and Notch, and participates in the 
induction of arterial differentiation 
(Lawson et al., 2002). Interestingly, Shh 
induces the expression of VEGF, Ang1 
and Ang2 (Pola et al., 2001). However, 
the major role of Shh in arterial differen-
tiation is to induce the expression of 
VEGF. At present, it is unclear whether 
VEGF is responsible for the initial speci-
fication of arterial progenitors or their 
subsequent differentiation. It has been 
speculated that continuous exposure to 
VEGF would induce the Notch signaling 
pathway, thereby increasing the level of 
grl in arterial progenitors (Lawson et al., 
2002). 
Angiogenesis in the adult 
In addition to its vital role during em-
bryogenesis, angiogenesis is required 
after birth for the growth of several or-
gans. Partial inhibition of VEGF by a 
soluble extracellular region of VEGFR-1 
resulted in increased mortality and im-
paired growth plate morphogenesis and 
endochondral bone formation in the 
early postnatal period (Gerber et al., 
1999). ECs of mature, quiescent vessels 
in the adult have a very low proliferation 
rate, with estimated turnover times 
measured in months or even years. 
However, new vessel growth occurs in 
some physiological conditions, such as 
in the female reproductive cycle and en-
docrine function of the ovarian corpus 
luteum (Ferrara et al., 1998). The ex-
pression of VEGFRs and Tie receptors is 
decreased in quiescent adult endothelium 
in comparison to embryonic endothe-
lium, and increased during periods of 
angiogenesis (Korhonen et al., 1992; 
Kremer et al., 1997; Otani et al., 1999; 
Wong et al., 1997). New vessels in the 
adult arise mainly through angiogenesis, 
although recent studies indicate that vas-
culogenesis, incorporation of endothelial 
cell precursors to the developing vessels, 
may also occur (Asahara et al., 1999; 
Asahara et al., 1997; Takahashi et al., 
1999).  
 
Angiogenesis is initiated by vasodilation 
and by an increase in vascular perme-
ability in response to angiogenic growth 
factors. VEGF has a central importance 
in this process.  Neovascularization of 
female reproductive system is largely 
mediated by hormonally induced expres-
sion of VEGF. In vessels undergoing 
active remodeling, the stabilizing func-
tion of Ang1 is overcome by an excess 
of Ang2 expression (Maisonpierre et al., 
1997). Ang2 expression makes endothe-
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lial cells prone to apoptosis. However, if 
VEGF is expressed simultaneously, en-
dothelial cells proliferate and form new 
vessels (Holash et al., 1999). At sites of 
active vessel growth e.g. in ovary and in 
tumors, Ang2 expression precedes that 
of VEGF. It has been speculated that 
Ang2 is able to trigger the detachment of 
pericytes, making ECs more vulnerable 
to angiogenic stimuli. In addition, VEGF 
induces the expression of EC surface 
integrins, which directly regulate EC in-
teractions with the ECM. Integrins are 
important for VEGF-driven angiogene-
sis, as blocking antibodies for EC sur-
face integrins inhibited neovasculariza-
tion (Senger et al., 1997). Once ECs are 
activated, they start to produce proteases 
that degrade the basement membrane 
and liberate growth factors sequestered 
within the ECM. These growth factors 
further stimulate the ECs to migrate, 
proliferate and to form new vessels. Fi-
nally the expression of PDGF-B gets 
upregulated in ECs to attract periendo-
thelial support cells and to stabilize the 
vessels. 
 
In addition to physiological angiogene-
sis, blood vessel growth is a major fea-
ture in many pathological conditions 
such as wound healing, ischemic heart 
diseases, diabetic retinopathy, tumor 
growth and metastasis. Angiogenesis is 
beneficial in wound healing and for the 
development of collateral vessels in 
ischemic diseases. Tissue ischemia in-
duces the expression of several angio-
genic growth factors and their receptors, 
thereby promoting angiogenesis 
(Semenza, 2001). In some pathological 
conditions, however, increased angio-
genesis is detrimental. These include 
diabetic retinopathy, rheumatoid arthritis 
and psoriasis. Although several mecha-
nisms regulating pathological and 
physiological blood vessel growth are 
alike, some molecules only minimally 
involved in embryonic vascular devel-
opment do affect pathological angio-
genesis (Carmeliet, 2000). One pair of 
such molecules is PlGF and VEGFR-1. 
Systemic application of PlGF, which 
mediates its effect only via VEGFR-1, 
enhances angiogenesis in ischemic adult 
tissues (Luttun et al., 2002). VEGF-B is 
another example, as VEGF-B deficient 
mice are overall healthy and fertile hav-
ing only very mild heart phenotypes 
(Aase et al., 2001; Bellomo et al., 2000). 
However, after coronary occlusion or 
myocardial ischemia, mice lacking 
VEGF-B show impaired recovery 
(Bellomo et al., 2000). Another differ-
ence between physiological and patho-
logical angiogenesis is that the latter is 
often induced by inflammation. For ex-
ample in healing wounds, inflammatory 
cells including macrophages, monocytes 
and leukocytes secrete cytokines stimu-
lating the proliferation and migration of 
endothelial cells and support cells (Frank 
et al., 1995).  
 
In order to grow beyond a few cubic mil-
limeters in size, tumors must promote 
new blood vessel growth (Folkman et 
al., 1996). Inhibitors of angiogenesis 
maintain a physiological balance with 
stimulators of endothelial proliferation. 
The switch from pre-vascular to angio-
genic state in tumors involves the disrup-
tion of this balance. In contrast to regular 
morphology and blood flow in normal 
vasculature, tumor vessels are disorgan-
ized and leaky and the tumor blood flow 
is chaotic and variable (Baish and Jain, 
2000; Hashizume et al., 2000; Morikawa 
et al., 2002). In several tumors, in-
creased vascularization has been directly 
correlated with poor prognosis. Angio-
genesis is also required for the estab-
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lishment and growth of metastases at 
secondary sites. In fact, a direct correla-
tion between tumor vascularity and me-
tastatic potential has been shown in a 
variety of tumor types, including non-
small cell lung carcinoma, breast carci-
noma and gliomas (Leon et al., 1996; 
Marcchiarini et al., 1992; Weidner et al., 
1991). 
 
The expression of many angiogenic 
growth factors and their receptors is 
upregulated in tumors (reviewed in 
Ferrara and Alitalo, 1999; Saaristo et al., 
2000). Overexpression of VEGF is a 
common feature of tumors, and specific 
inhibition of its function by a blocking 
monoclonal antibody inhibits tumor vas-
cularization and growth (Kim et al., 
1993). Interruption of VEGFR-2 or Tie2 
signaling pathways via delivery of 
dominant-negative VEGFR-2 receptor or 
soluble extracellular domains of 
VEGFR-1 or Tie2 inhibits tumor growth 
in mice, indicating importance of these 
receptors for tumor angiogenesis 
(Goldman et al., 1998; Lin et al., 1997; 
Lin et al., 1998a; Millauer et al., 1996; 
Millauer et al., 1994; Siemeister et al., 
1999). Also VEGFR-3 is expressed in 
capillary vessels in tumor angiogenesis 
(Partanen et al., 1999a; Valtola et al., 
1999). Inactivation of VEGFR-3 by neu-
tralizing antibodies supresses tumor 
growth by destabilizing tumor-asso-
ciated angiogenic vessels, without af-
fecting the established blood and lym-
phatic vasculature (Kubo et al., 2000).  
1.2.2 The lymphatic system 
Lymphatic system collects extravasated 
fluid and lymphocytes from the tissues 
into blind-ended lymphatic capillaries, 
and transports them back to the blood 
circulation (Fig. 3). Unlike the blood 
vasculature, which forms a circulatory 
loop, the lymphatic system forms a one-
way transit system. The structure of 
lymphatic capillaries is also different 
from blood capillaries, reflecting the dif-
ference in their function (Fig. 3). Lym-
phatic capillaries consist of an extremely 
permeable, thin EC layer that is often 
devoid of surrounding support cells and 
basement membrane. Anchoring fila-
ments connect lymphatic ECs to the 
ECM and hold the vessels open when 
the pressure rises in the interstitial tissue 
(Swartz, 2001). From these small lym-
phatic vessels, lymph is transferred to 
progressively larger collecting lymphat-
ics, consisting of endothelial, muscular 
and adventitial layers, and ultimately 
into the venous circulation via the tho-
racic duct. In addition to the lymphatic 
vessels, the lymphatic system also con-
tains several lymphoid organs (spleen, 
lymph nodes, tonsils and thymus) that 
are essential in immune responses. Fur-
thermore, lymphatic vessels participate 
in absorption of lipids from the gut 
(Witte et al., 2001).  
Development of the lymphatic vessels  
The development of the lymphatic vas-
cular system begins in the fifth week of 
embryonic life in humans. When the 
embryo grows, lymphatic vessels are 
needed for the regulation of the intersti-
tial tissue pressure. According to present 
data, lymphatic vessels originate from 
lymph sacs, which are formed by endo-
thelial sprouting from the veins (Dumont 
et al., 1998; Wigle et al., 1999) (Fig. 4). 
It is also possible that lymphangioblasts 
exist and participate in lymphatic vessel 
development in mammals. In avians 
primitive lymphangioblasts, which dif-
ferentiate from the mesenchyme in situ 
to lymphatic endothelial cells, have been 
identified and these cells can be re-
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cruited by the developing lymphatic ves-
sels (Schneider et al., 1999). 
 
Recently, various markers specific for 
the lymphatic endothelium have been 
characterized, enabling the study of 
lymphatic vascular development. The 
first indication of lymphangiogenesis is 
seen around E9.5 in mouse, when the 
expression of a homeobox transcription 
factor Prox-1 begins. Prox-1 has an im-
portant role in the formation of the 
lymph sacs by endothelial sprouting 
from the veins (Wigle et al., 2002; 
Wigle and Oliver, 1999). Mice deficient 
of Prox-1 do not develop any lymphatic 
vessels, which results in severe edema at 
midgestation and death around E14.5 
(Wigle and Oliver, 1999). Further sup-
port for the importance of Prox-1 in de-
fining lymphatic EC characteristics came 
from studies of cultured cells. Recently 
techniques allowing the isolation of pri-
mary human blood and lymphatic ECs 
have been developed (Kriehuber et al., 
2001; Mäkinen et al., 2001b). The gene 
expression  profiles in these two cell 
populations have been analyzed and a 
number of genes were found to be dif-
ferentially expressed (Petrova et al., 
2002). Interestingly, ectopic overexpres-
sion of Prox-1 in blood ECs induces the 
expression of about one third of lym-
phatic EC-specific genes, indicating that 
Prox-1 is an important regulator of lym-
phatic differentiation (Petrova et al., 
2002). After the initial budding from 
embryonic veins, lymphatic ECs start to 
express additional lymphatic endothelial 
markers, and the simultaneous expres-
sion of LYVE-1, Prox-1, VEGFR-3 and 
SLC in ECs indicates commitment to the 
lymphatic EC lineage (Wigle et al., 
2002).  
 
Figure 4. Embryonic lymphatic vascular development. Florence Sabin proposed already in 1902 that 
primitive lymph sacs form by sprouting from embryonic veins. Peripheral lymphatic system then spreads 
from these lymph sacs. Also lymphatic precursor cells (lymphangioblasts) differentiating in situ from the 
mesenchyme to form lymphatic endothelial cells may exist and participate in lymphatic vessel formation. 
Adapted from Saaristo, 2002b. 
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The expression of VEGFR-3 is main-
tained in budding lymphatic ECs, while 
its expression becomes weaker in the 
blood vasculature. VEGFR-3 expression 
is largely restricted to the lymphatic en-
dothelium around E14 in mouse devel-
opment (Kaipainen et al., 1995). A 
paracrine expression pattern is seen be-
tween VEGF-C and VEGFR-3 at sites 
where the first lymphatic sprouts occur, 
suggesting that VEGF-C and VEGFR-3 
play a major role in the development of 
lymphatic vessels (Kukk et al., 1996). 
The expression pattern of the other 
ligand for VEGFR-3, VEGF-D, has not 
been studied in detail but its mRNA has 
been observed in the developing 
melanocytes and fibroblasts, lung mes-
enchyme and in the adult vascular wall 
(Achen et al., 2001). Whether the func-
tion of VEGF-C and/or VEGF-D is criti-
cal for the lymphatic vessel development 
remains to be ascertained as the pheno-
types of VEGF-C and VEGF-D null 
mice have not been published yet.  
 
In addition to VEGFR-3, VEGFR-1 and 
VEGFR-2 are also expressed in lym-
phatic endothelium (Mäkinen et al., 
2001b; Saaristo et al., 2002a). However, 
VEGFR-3 expression pattern differs 
from the two other VEGFRs, as it is 
relatively specific for lymphatic endo-
thelial cells. Few exceptions to the lym-
phatic VEGFR-3 expression pattern are 
known, as it is expressed in some fenes-
trated blood endothelial cells and angio-
genic blood vessels in breast tumors 
(Partanen et al., 2000; Valtola et al., 
1999). The importance of VEGFR-3 for 
lymphatic vessel development is illus-
trated by the results from several trans-
genic mouse studies. Mice expressing 
soluble ligand binding part of the 
VEGFR-3 in the skin keratinocytes have 
normal blood vasculature, but lack der-
mal lymphatics (Mäkinen et al., 2001a). 
In contrast, overexpression of VEGF-C 
or VEGF-D resulted in hyperplasia of 
the superficial lymphatic vessels, again 
without any blood vascular effects 
(Jeltsch et al., 1997; Veikkola et al., 
2001). Interestingly, overexpression of a 
mutant form of VEGF-C (VEGF-C156S) 
that is a specific ligand for VEGFR-3 
also leads to lymphatic dilation in trans-
genic mice, indicating that signaling via 
VEGFR-3 alone is sufficient for lym-
phangiogenesis in vivo (Veikkola et al., 
2001).  
 
There are differences in the expression 
patterns of VEGFR-2 and VEGFR-3 in 
different types of lymphatic vessels. 
VEGFR-3 is highly expressed by the ini-
tial lymphatic capillaries while VEGFR-
2 expression is highest in the collecting 
lymphatic vessels in the adults (Saaristo 
et al., 2002a). To date, there is no pub-
lished data on lymphatic VEGFR-1 ex-
pression in vivo. Like VEGF, VEGF-C 
increases vascular permeability and 
stimulates EC migration and prolifera-
tion but at higher concentrations than 
VEGF (Mäkinen et al., 2001b). VEGF-
C156S and VEGF-D, on the other hand, 
have been reported to be inactive in the 
permeability assay (Achen et al., 1998; 
Joukov et al., 1998). The lymphatic ef-
fects induced by VEGF-C and VEGF-
C156S overexpression in vivo are differ-
ent. While VEGF-C156S overexpression 
results in lymphatic hyperplasia, VEGF-
C induces intensive lymphatic sprouting, 
suggesting that VEGFR-2 activation 
may be required for efficient induction 




Recent findings indicate that Ang2 me-
diates lymphangiogenic signals although 
it is not required for the initial formation 
of lymphatics (Gale et al., 2002). Ang2 
deficient mice die by two weeks of age 
due to lymphatic defects. The large mes-
enteric lymphatic vessels are poorly as-
sociated with SMCs, and the smaller 
lymphatic vessels in the gut and in the 
skin are disorganized and irregular. Mice 
having Ang2 gene replaced by Ang1 
have no lymphatic defects, suggesting 
that Ang2 functions as an agonist in 
lymphatic ECs. Both Tie receptors are 
expressed at least in some lymphatic 
ECs in human fetal heart (Partanen et 
al., 1999b). Also, Tie1 is expressed in 
the lymphatic vessels in K14-VEGF-C 
transgenic mice (Jeltsch et al., 1997). 
However, no lymphatic defects have 
been characterized in Tie deficient mice, 
probably due to embryonic death caused 
by vascular defects before the lymphatic 
phenotype would appear. 
 
In addition to Ang2 knockouts, mice 
with a targeted disruption of Net, a 
member of Ets transcription factors, or 
integrin α9, die neonatally because of 
lymph drainage problems (Ayadi et al., 
2001; Huang et al., 2000). At present, it 
is not known whether Net and integrin 
α9 regulate lymphatic vessel function 
via VEGFRs or Tie receptors or via al-
ternative unidentified pathways. 
Lymphangiogenesis in the adult 
Lymphangiogenesis appears to follow 
but lag behind angiogenesis in adult tis-
sues. In healing skin wounds, VEGFR-3 
positive lymphatic vessels sprout from 
pre-existing lymphatics and grow into 
the granulation tissue (Paavonen et al., 
2000). The reason for the delay in lym-
phatic vessel growth in comparison to 
blood vessel growth may be the fact that 
blood vascular endothelial cells produce 
VEGF-C, which is needed to attract 
lymphatic vessels (Kriehuber et al., 
2001; Mäkinen et al., 2001b).  
 
Abnormal lymphatic vessel development 
and function are associated with human 
lymphedema. Lymphedema is character-
ized by disfiguring and disabling swell-
ing of the limbs due to defective lym-
phatic drainage. Several missense muta-
tions within the VEGFR3 region have 
been linked to human primary lymphe-
dema (Irrthum et al., 2000; Karkkainen 
et al., 2000). Other genetic loci are 
linked to other lymphedema syndromes. 
Lymphedema-distichiasis, for example, 
has been linked to mutations in the 
FOXC2 gene (Fang et al., 2000). 
FOXC2 is a transcription factor but so 
far it is not known how it regulates lym-
phatic vessel growth  or function. Mice 
deficient of Foxc2 did not give an an-
swer to that question, as they die during 
embryogenesis or perinatally due to vas-
cular defects and do not have lymphe-
dema (IIda et al., 1997; Winnier et al., 
1997). Although several mutations have 
been linked to lymphedema, the most 
common form of lymphedema is not ge-
netic but results from filarial worm in-
fection causing the obstruction of lym-
phatics.  
 
The lymphatic system serves as the pri-
mary pathway for metastatic spread of 
tumor cells to regional lymph nodes. Re-
cent studies in mice have indicated that 
overexpression of VEGF-C or VEGF-D 
in tumors leads to extensive lymphan-
giogenesis in/around tumors and it is as-
sociated with increased frequency of me-
tastases (Karpanen et al., 2001; Mandri-
ota et al., 2001; Skobe et al., 2001; 
Stacker et al., 2001). However, it is still 
unclear whether VEGF-C or VEGF-D 
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induce lymphangiogenesis in human tu-
mors and whether tumor lymphangio-
genesis plays an important role in tumor 
growth and metastasis in humans. A cor-
relation has been found between VEGF-
C expression and formation of metasta-
sis in several human cancers, suggesting 
that this may be the case (Akagi et al., 




2 REGULATION OF ENDOTHELIAL CELL-SPECIFIC EXPRESSION OF 
GENES 
2.1 Characterization of regulatory elements of endothelial specific genes 
Gene expression can be controlled at 
several stages, such as transcription, 
hnRNA processing, translation and post-
translational modification. The promot-
ers of eukaryotic protein-encoding genes 
utilize a large combinatorial array of 
DNA elements and protein transactiva-
tors as receivers of physiological cues to 
direct spatial and temporal programs of 
gene expression. Transcription is con-
trolled at the stage of initiation, as a re-
sult of modulation of  transcription fac-
tor expression or post-translational 
modifications. Transcription factors can 
activate RNA polymerase II driven tran-
scription via a promoter or an enhancer. 
The promoter determines the site of tran-
scriptional initiation, which is carried out 
when transcription factors bind to the 
DNA sequence close to and upstream of 
the start site. The enhancer stimulates 
promoters in a temporally regulated or 
tissue-specific manner, when transcrip-
tion factors bind to specific sequences 
distal to and either upstream or down-
stream from the start site (Blackwood 
and Kadonaga, 1998). In contrast to the 
promoter, enhancer functions in an ori-
entation independent manner. There are 
several possibilities how enhancers regu-
late gene expression. Enhancers may 
stimulate promoters by relieving chro-
matin-mediated repression, a process 
that may involve histone acetylation. 
They may be responsible for locating the 
template at a particular place within the 
cell. Enhancers can also function in 
stimulating DNA replication. Cell type 
specific expression can be regulated also 
via silencers, which inhibit the transcrip-
tion of certain genes in other than target 
tissues.  
 
Although significant progress has been 
made in determining the role of endothe-
lial cell surface molecules in the process 
of vascular development, little is known 
about the mechanisms of differentiation 
and maturation of ECs. However, during 
the last few years, the cis-acting DNA 
elements and trans-acting protein factors 
that regulate transcription of several EC-
specific genes have been identified and 
partially characterized.  The results from 
these studies are summarized below. 
2.1.1 The Tie genes 
Both Tie1 and Tie2 are expressed al-
ready in the embryonic angioblasts and 
continue to be expressed mainly in the 
vascular endothelium throughout em-
bryonic development. However, Tie re-
ceptors are also expressed in some he-
matopoietic stem cells and B-cells as 
well as in leukemic cell lines (Armstrong 
et al., 1993; Hashiyama et al., 1996; 
Iwama et al., 1993; Kukk et al., 1997; 
Yano et al., 1997). In comparison to the 
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embryonic vasculature, Tie1 and Tie2 
expression is downregulated in quiescent 
adult endothelia, although receptors can 
be detected in most adult endothelia as 
well.  
 
The genomic regulatory regions of Tie1 
and Tie2 necessary for targeting gene 
expression specifically to the endothe-
lium have been identified (Korhonen et 
al., 1995; Schlaeger et al., 1997) (Fig. 
5). Neither Tie1 nor Tie2 promoters con-
tain TATA or CAAT boxes, which are 
often present in promoter elements. The 
5´ regions of both mouse and human 
Tie1 genes have been partially character-
ized and the promoter fragments suffi-
cient to target expression of heterolo-
gous genes specifically to ECs in vivo 
have been determined (Korhonen et al., 
1995). Analysis of transgenic mice ex-
pressing a LacZ reporter gene driven ei-
ther by a 0.8 kbp mouse Tie1 promoter 
fragment or by a 5 kbp human TIE1 
promoter fragment showed activity in 
endothelia throughout development and 
in adulthood (Korhonen et al., 1995). 
Comparison of mouse and human Tie1 
promoter sequences revealed several 
conserved putative binding sites for tran-
scription factors conforming to Ets and 
AP-2 families as well as a GT-rich re-
gion and an octameric element, indicat-
ing that these DNA elements might have 
a regulatory role.  
 
 
Figure 5. Regulatory elements of Tie1 and Tie2 genes. In Tie1, 0.8 kbp proximal promoter is needed to 
target gene expression specifically to endothelial cells. In Tie2, the endothelial regulatory elements are dis-
tributed in both the proximal promoter and in the large first intron (particularly in the 303 bp NcoI-XbaI 
fragment). The regulatory regions share several DNA motifs including putative binding sites for the Ets 
transcription factors as well as an octamer factor binding site. In addition, a putative transcription factor 
binding site for AP-2 is found in the Tie1 promoter and sites for Oct-1, NF-S, bZIP and CP2−γ are found in 
the Tie2 promoter/intronic enhancer. White boxes indicate the non-coding portions of the first exons and 
black boxes indicate the coding sequences; the arrows with ATG indicate the sites of the translational ini-
tiation codons. Adapted from Jones et al., 2001.   
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Similar transgenic mouse experiments 
with the LacZ reporter have been carried 
out with several 5´ flanking fragments of 
mouse Tie2. In the case of Tie2, a 1.2 
kbp promoter fragment was sufficient to 
drive reporter gene expression in endo-
thelia in the early embryonic stages 
(Schlaeger et al., 1995). The EC-specific 
activity of Tie2 promoter has been lo-
cated to a 223 bp 5´ untranslated region, 
as deletion of that region abolished the 
EC-specific activity in vivo (Schlaeger et 
al., 1995). Further analysis of this criti-
cal Tie2 promoter region revealed the 
importance of a consensus octamer bind-
ing element. Based on results from 
EMSA experiments, this octamer forms 
a complex with an ubiquitous factor 
Oct1 and an EC-specific cofactor (Fadel 
et al., 1999). Moderate reporter gene ac-
tivity driven by the 2.1 kbp Tie2 pro-
moter was observed also in the brain and 
kidney of adult mice, whereas the regu-
latory elements present within the first 
intron of Tie2 were needed for more ex-
tensive expression in both embryonic 
and adult endothelium (Evans et al., 
2000; Schlaeger et al., 1997) (Fig. 5). 
An internal 1.7 kbp intronic fragment 
was identified as an autonomous EC-
specific enhancer, as it could activate 
heterologous tk promoter in both orienta-
tions in the endothelia of transgenic mice 
(Schlaeger et al., 1997). The core enhan-
cer activity in the Tie2 intronic sequence 
was found to be located within a 303 bp 
fragment. Sequence analysis of this 
fragment revealed the presence of sev-
eral putative binding sites for general 
and tissue-specific transcription factors 
(Fig. 5). Mutational analysis of these 
sites indicated that the octameric palin-
drome and the putative NF-S site regu-
late the integration site dependency of 
the reporter construct, whereas muta-
tions made either to the single Ets bind-
ing site (EBS) or to the region contain-
ing putative sites for bZIP, CP2-gamma 
and two EBSs render the enhancer com-
pletely inactive (Schlaeger et al., 1997).  
 
Both Tie1 and Tie2 protein levels are 
increased by hypoxia (McCarthy et al., 
1998; William et al., 2000). Hypoxic 
activation of Tie2 is mediated most 
likely at least partly by the hypoxia-
inducible factor-1α (HIF1α)-related 
transcription factor HIF-2/EPAS1/HRF. 
HIF-2 is expressed in the endothelium 
and its cotransfection strongly induces 
the Tie2 promoter/enhancer activity 
(Schlaeger et al., 1997; Tian et al., 
1997).  
2.1.2 The VEGFR1 and VEGFR2 
genes 
The expression patterns of VEGFR1 and 
VEGFR2 are quite similar to each other 
as both receptors are expressed primarily 
in ECs, their expression is downregu-
lated in adult endothelia and up-
regulated during tumor angiogenesis. 
However, some differences have been 
detected for example in the fetal human 
heart, as only VEGFR1 was expressed in 
coronary endothelium (Kaipainen et al., 
1993; Partanen et al., 1999b). There are 
also differences in the non-endothelial 
expression pattern of VEGFRs, as 
VEGFR1 is expressed in macrophages, 
monocytes, trophoblasts and renal me-
sanglial cells, whereas VEGFR2 is ex-
pressed in hematopoietic stem cells, 
megakaryocytes, platelets and retinal 
progenitor cells (Barleon et al., 1996; 
Charnock-Jones et al., 1994; Clauss et 
al., 1996; Katoh et al., 1995; Takahashi 
et al., 1995; Yang and Cepko, 1996; 
Ziegler et al., 1999).  
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Figure 6. Schematic structure of VEGFR1 and Vegfr2 regulatory regions. In VEGFR1 promoter the 
critical region for EC-specific expression contains a TATA box, one CRE motif, two GC boxes and multi-
ple Ets binding sites. The promoter region of Vegfr2 contains multiple binding sites for transcription factors 
conforming to Ets, AP-2, NF-κB and GATA families as well as two HIF binding sites (HBSs). Transcrip-
tion factor binding sites including several GATA, Scl/Tal-1 and Ets sites present within the EC-specific 
enhancer, which is located immediately upstream of the second exon are indicated. The critical transcrip-
tion factor binding sites are pointed out by arrowheads, see text for details. 
 
The 5´ flanking regions of both mouse 
and human VEGFR1 have been cloned 
and partially characterized. The 2.2 kbp 
mouse Vegfr1 promoter fragment directs 
endothelial specific reporter gene ex-
pression in embryoid bodies (Quinn et 
al., 2000). EC-restricted reporter gene 
expression is detected also by the 1 kbp 
human VEGFR1 promoter fragment after 
adenoviral cell delivery ex vivo (Nicklin 
et al., 2001). Furthermore, this promoter 
fragment is sufficient for directing wide-
spread vascular expression in the em-
bryo and in the endothelium of most or-
gans in adult mice (Minami et al., 2002). 
VEGFR1 promoter has a TATA box, and 
an approximately 200 bp sequence up-
stream of exon 1 was found to confer 
endothelial cell type specific reporter 
gene expression in cultured cells (Fig. 6) 
(Ikeda et al., 1996; Morishita et al., 
1995). This region contains several mo-
tifs for transcription factors including 
one cAMP response (CRE)/ATF ele-
ment, several EBS and two GC boxes 
(Ikeda, 1996 et al.; Morishita et al., 
1995). Mutation of the CRE or single 
EBS just downstream of CRE decreased 
the basal activity by 90% (Wakiya et al., 
1996). Of the Ets factors, Ets1, Ets2 and 
Erg are able to stimulate VEGFR1 pro-
moter activity in vitro (Dube et al., 
1999; Wakiya et al., 1996). Both the 
CRE motif and EBS need to be intact for 
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efficient Ets transactivation, indicating 
cooperative relations between these mo-
tifs in the VEGFR1 promoter (Wakiya et 
al., 1996). Interestingly, positive correla-
tion was observed between ETS1 and 
VEGFR1, but not with VEGFR2 expres-
sion in the endothelial cells of human 
gliomas (Valter et al., 1999). Targeted 
inactivation of JunB, a  member of the 
AP-1 transcription factor family,  leads 
to defective yolk sac vascularization in 
mouse embryos due to reduced Vegfr1 
expression (Schorpp-Kistner et al., 
1999). The Jun proteins form either 
homo- or heterodimers with members of 
the Fos and ATF protein families (Vogt 
and Bos, 1990). However, when co-
transfected with other members of the 
AP-1 transcription factor complex, c-Fos 
and c-Jun do not transactivate the 
VEGFR1 promoter fragment containing 
the CRE motif (Wakiya et al., 1996). 
The first intron of the VEGFR1 nega-
tively regulated gene expression, possi-
bly due to transcriptional arrest 
(Morishita et al., 1995).  
 
Also the regulatory elements of the 
mouse and human VEGFR2 have been 
identified (Kappel et al., 1999; Patterson 
et al., 1995; Ronicke et al., 1996). A 4 
kbp fragment of VEGFR2 promoter di-
rected high level luciferase activity in 
endothelial cells but not in other cell 
types (Patterson et al., 1995). Similarly, 
the 2.2 kbp Vegfr2 promoter showed 
strong endothelium specific activity in 
transfected cells (Ronicke et al., 1996). 
The VEGFR2 promoters contain no 
TATA consensus sequence but they are 
GC rich and contain several Sp1 ele-
ments. Single transcription start sites 
were identified in human and mouse 
promoters, located 303 bp and 299 bp 5’ 
of the translational start, respectively. 
Results from in vivo footprinting ex-
periments suggest that Sp1 participates 
in cell type specific VEGFR2 expression 
as Sp1 sites are occupied only in endo-
thelial cells (Patterson et al., 1997). 
Transient transfection assays with sev-
eral VEGFR2 promoter-reporter con-
structs revealed additional positive regu-
latory elements with conserved potential 
binding sites for AP-2, NF-κB and E-
Box proteins (Patterson et al., 1995). 
Transactivation studies indicate that Ets1 
and Ets2 can activate the 0.9 kbp Vegfr2 
promoter fragment (Kappel et al., 2000). 
Ets1 transactivates Vegfr2 promoter via 
two of the six putative EBSs (Kappel et 
al., 2000). One of these two EBSs is re-
quired to target high level reporter gene 
expression to ECs in vivo (Kappel et al., 
2000). In addition to EBSs, the Vegfr2 
promoter region needed for adequate 
promoter activity in cultured cells has 
several AP-2 sites and one potential NF-
κB site (Fig. 6) (Ronicke et al., 1996).  
 
Despite the activity in cultured ECs, 
Vegfr2 promoter sequences are not suffi-
cient to confer reproducible EC-specific 
reporter gene expression in vivo (Kappel 
et al., 1999). However, in combination 
with a 2.3 kbp fragment from the first 
intron of the Vegfr2 gene, the 0.9 kbp 
Vegfr2 promoter could drive reporter 
gene expression specifically in ECs in 
transgenic mice throughout the devel-
opment (Kappel et al., 1999). The 
proximal Vegfr2 promoter mainly con-
tributes to strong and position-
independent reporter gene expression, 
while the EC-specificity of Vegfr2 is 
mediated by the intronic enhancer. A 
430 bp sequence of the intronic enhancer 
is sufficient for targeting endothelial-
specific reporter gene expression in vivo. 
Several potential binding sites for the 
transcription factors of Scl/Tal-1 (Stem 
cell leukemia/T-cell acute leukemia), 
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GATA and Ets families are located in 
the minimal enhancer (Fig. 6). Scl/Tal 
and GATA transcription factors have 
been proposed to play a role in vascu-
logenesis and angiogenesis (Dorfman et 
al., 1992; Drake et al., 1997; Gering et 
al., 1998; Liao et al., 1998). The muta-
tion of a single GATA site or a single 
EBS results in the complete loss of en-
dothelial specificity of the minimal en-
hancer in vivo, whereas the mutation of 
either one of the two Scl/Tal-1 binding 
motives reduces reporter gene expres-
sion (Kappel et al., 2000). Analysis of 
protein-DNA interactions on the Vegfr2 
enhancer suggests that all of these poten-
tial transcription factor binding sites are 
functional, as specific complexes are 
formed (Kappel et al., 2000). DNase 
footprinting experiments demonstrate an 
EC-specific interaction of nuclear pro-
teins with the EBS. However, transacti-
vation studies indicate that Ets1 and Ets2 
can not activate the Vegfr2 enhancer in 
vitro. 
 
Taken together, the DNA sequences of 
the 5´ flanking region of VEGFR1 and 
VEGFR2 genes have only a few com-
mon features, indicating that these genes 
are likely to be differentially regulated. 
Also the hypoxic induction of these two 
genes is mediated via different transcrip-
tion factors. VEGFR1 transcription is 
upregulated via the HIF-1α binding site 
present within the promoter region, 
while Vegfr2 promoter driven transcrip-
tion is stimulated by HIF-2α in hypoxic 
conditions (Gerber et al., 1997; Kappel 
et al., 1999). HIF-2α and Vegfr2 are co-
expressed in postnatal mouse brain cap-
illaries (Elvert et al., 2002). Recently, 
HIF-2α has been shown to bind to two 
HRE-related sequences or HIF-2 binding 
sites (HBSs) located in close proximity 
to EBSs in the Vegfr2 promoter (Fig. 6). 
HIF-2α and Ets1 interact physically with 
each other and stimulate the Vegfr2 
promoter activity in a synergistic manner 
in vitro (Elvert et al., 2002). 
 
2.1.3 The VE-cadherin, PECAM-1 
and VWF genes 
VE-cadherin 
 
Endothelial cells use cell adhesion mole-
cules such as cadherins, selectins and 
integrins to attach themselves to one an-
other and to the parenchyma. Cadherins 
are localized to structures known as ad-
herens junctions. Although at least 3 
cadherins have been found to be ex-
pressed in ECs, vascular endothelial 
(VE)-cadherin is the only one expressed 
specifically in ECs in various types of 
endothelia. VE-cadherin is expressed 
already at the very earliest stages of vas-
cular development (E7.5 in mouse) in 
the blood islands and allantois of mouse 
embryos and it continues to be expressed 
in the vascular endothelium of most of 
the organs during development and in 
adulthood (Breier et al., 1996). In con-
trast to most endothelial markers, it is 
not expressed in blood cells or in hema-
topoietic precursors. In embryonic stem 
cell-derived embryoid bodies, VE-
cadherin null mutation inhibits the as-
sembly of vascular-like structures, sug-
gesting that VE-cadherin has an impor-
tant role in vascular morphogenesis 
(Vittet et al., 1997). Furthermore, gene 
targeting studies have revealed the vital 
role of VE-cadherin in vascular devel-
opment, as inactivation of VE-cadherin 
gene results in early lethality of embryos 
with absence of differentiation of blood 
islands of the yolk sac into a primary 
vascular plexus (Carmeliet et al., 1999; 
Gory-Faure et al., 1999).  
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Approximately 2.5 kbp of the mouse 
VE-cadherin promoter region is suffi-
cient to drive the expression of a reporter 
gene specifically in the ECs of trans-
genic mice (Gory et al., 1999). Analysis 
of the proximal region of the promoter 
revealed the presence of three regulatory 
regions; one acts as a ubiquitous pro-
moter and two regions silence the tran-
scriptional activity in non-endothelial 
cells (Gory et al., 1999) (Fig. 7). VE-
cadherin promoter lacks TATA and 
CAAT boxes but has a GT box in prox-
imity of a unique transcriptional start site 
(Gory et al., 1998; Huber et al., 1996). 
GT box is a consensus binding site for 
the Sp1 family of transcription factors. 
Sp1 is able to recruit TATA-binding pro-
tein and associated factors to the initia-
tion complex. DNA-protein interaction 
studies indicated that Sp1 and Sp3 
formed complexes with the GT box of 
VE-cadherin promoter. GT motif is a 
major determinant of VE-cadherin pro-
moter activity as mutation of it caused 
80% reduction in transcriptional activity. 
In addition, five EBSs were identified in 
the VE-cadherin promoter by sequence 
analysis. Two of these were determined 
to be essential for VE-cadherin promoter 
activity, as site-directed mutagenesis of 
either one of the EBSs reduced VE-
cadherin promoter driven reporter gene 
expression dramatically in cultured cells 
(Gory et al., 1998). Based on EMSA ex-
periments, Erg forms a complex with 
one of the essential EBSs while Ets1 
binds to both (Gory et al., 1998; Lelièvre 
et al., 2000). Overexpression of Ets1 re-
sulted in the upregulation of VE-
cadherin expression, thereby reducing 
EC density at confluence via its associa-
tion with beta-catenin (Lelièvre et al., 
2000).  
  
Platelet endothelial cell adhesion mole-
cule-1 
 
Platelet endothelial cell adhesion mole-
cule-1 (PECAM-1 or CD31) is a trans-
membrane protein belonging to the Ig 
gene superfamily. PECAM-1 has been 
widely used as a ubiquitous endothelial 
marker as it is highly expressed in ECs. 
However, also platelets, a subgroup of 
leukocytes, and hematopoietic precur-
sors are PECAM-1 positive. PECAM-1 
has important functions in angiogenesis, 
vascular injury repair, and control of the 
leukocyte extravasation.  
 
The 5' flanking region of the human 
PECAM-1 gene has been isolated and 
studied in cultured cells (Almendro et 
al., 1996; Gumina et al., 1997) (Fig. 7). 
An Alu sequence is located at the 5´-end 
of the promoter which lacks a consensus 
TATA box and CAAT element. Several 
transcription initiation sites were identi-
fied up to 601 bp upstream from the 
translation start site (Almendro et al., 
1996; Gumina et al., 1997; Kirschbaum 
et al., 1994). Many putative cis-acting 
control elements are present within the 
5´ flanking region of PECAM-1 gene. 
These include several EBSs, GC-rich 
sequences, GATA sites, an Sp1 site, and 
an AP-2 binding site (Fig. 7). Two con-
tinuous fragments driving gene expres-
sion either to the myeloid lineage (0.22 
kbp NheI-BglII) or to the ECs (0.44 kbp 
BglII-PstI) were identified from the 
promoter (Almendro et al., 1996). The 
0.22 kbp fragment exhibited PMA in-
ducibility in myeloid cells and contained 
a PMA-responsive element recognized 
by Sp1 and EGR-1 transcription factors. 
Mutational analysis showed that a cer-
tain NF-κB site and one of the GATA 
sites are important for PECAM-1 pro-
moter activity in cultured cells (Botella 
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et al., 2000; Gumina et al., 1997). Re-
sults from EMSA experiments have 
given further support for the functional-
ity of these sites, as NF-κB and GATA2 
were able to bind to their respective rec-
ognition sequences of the PECAM-1 
promoter (Botella et al., 2000; Gumina 
et al., 1997). 
 
 
Figure 7. Schematic structure of VE-cadherin, PECAM-1 and VWF regulatory regions. The three 
functional domains of VE-cadherin promoter sufficient to drive EC-specific expression in vivo are indi-
cated as roman numbers (I, minor inhibitory region; II, major inhibitory region; III, basal promoter region). 
The basal promoter has one binding motif for Sp1/Sp3 factors, indicated as a GT box and several EBSs. 
Regulatory elements of PECAM-1 are located in the 5´ flanking region, exon 1 and in the beginning of the 
first intron. The ATG translation start codon followed by the first exon (black box) is indicated. The human 
VWF promoter transcriptional activators located within the 90 bp core promoter are indicated in the figure. 
The critical transcription factor binding sites of VE-cadherin and PECAM-1 promoters are pointed out by 
arrowheads while all the DNA elements of VWF promoter marked to the figure are important for its func-
tion. The Alu sequences present in PECAM-1 and VWF promoters are represented as grey boxes. 
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von Willebrand factor 
 
von Willebrand factor (vWF) is a mul-
timeric glycoprotein that mediates adhe-
sion of platelets to the underlying endo-
thelium and serves as a carrier for the 
coagulation factor VIII. Expression of 
the vWF gene is restricted to the endo-
thelium, megakaryocytes and platelets. 
vWF expression has been commonly 
taken as a proof for endothelial nature of 
a cell. However, vWF is not uniformly 
expressed in the endothelium and is 
therefore a marker of endothelial cell 
heterogeneity (Yamamoto et al., 1998).  
 
Both mouse and human VWF promoter 
regions have been isolated and they are 
highly homologous in both structure and 
function. Sequence analysis revealed the 
presence of TATA and CAAT boxes and 
the human VWF promoter has Alu se-
quences 5´ to the transcription initiation 
site (Assouline et al., 1988). The results 
from transgenic mouse studies indicate 
that VWF gene is regulated in a modular 
fashion from one vascular bed to an-
other. The 0.7 kbp fragment of human 
VWF promoter, including 0.5 kbp of the 
5´ flanking sequence and the first exon, 
targeted reporter gene expression to a 
subpopulation of ECs in the yolk sac and 
to blood vessels of the brain (Aird et al., 
1995). A larger promoter fragment con-
taining the 2.2 kbp 5’ flanking sequence, 
the first exon, and the first intron di-
rected the reporter gene expression also 
to the microvasculature of the heart and 
skeletal muscle (Aird et al., 1997) (Fig. 
7). Similar reporter gene expression pat-
tern was detected with the regulatory 
regions of the mouse vWf gene located 
between the 2.6 kbp 5´ flanking region 
and the 3´-end of the first intron of the 
vWf (Guan et al., 1999). The 5´ flanking 
regions and the first exons of the VWF 
genes have several conserved putative 
transcription factor binding sites includ-
ing one GATA motif and two EBSs 
(Guan et al., 1999; Jahroudi and Lynch, 
1994; Schwachtgen et al., 1997). Muta-
tional analysis indicated that these DNA 
elements regulate VWF gene expression 
(Jahroudi and Lynch, 1994; 
Schwachtgen et al., 1997). Of the Ets 
factors, Ets1 and Erg were able to trans-
activate a VWF core promoter construct, 
and EMSA studies further confirmed the 
interaction of these Ets factors with 
EBSs of VWF (Schwachtgen et al., 
1997). However, the core promoter is 
not sufficient to restrict VWF expression 
to ECs. Additional inhibitory regions 
containing NF-1, Oct-1 and NF-Y motifs 
are needed to repress VWF transcription 
in non-endothelial cells (Jahroudi et al., 
1996; Peng and Jahroudi, 2002; 
Schwachtgen et al., 1998). DNA-protein 
interaction studies suggest that these rep-
ressors have inhibitory functions on the 
VWF promoter in all cell types, but ECs 
have a mechanism to overcome the inhi-
bition (Peng and Jahroudi, 2002). 
 
2.1.4 Other genes predominantly ex-
pressed in endothelial cells  
The 5´ flanking regions of many other 
genes predominantly expressed in ECs 
have been partially characterized. In 
most cases, the regulatory elements have 
been studied only in cultured cells and 
are not discussed here. However, the re-
sults from studies on EC-specific regula-
tory elements targeting vascular endo-








Endoglin (ENG) is a cell surface com-
ponent of TGF-ß receptor complex 
highly expressed by ECs and in lesser 
amount on some hematopoietic cells, 
syncytiotrophoblasts of placenta and 
stromal cells (Ríus et al., 1998). The 3.3 
kbp ENG promoter lacks consensus 
TATA and CAAT boxes, but contains 
two GC-rich regions and a consensus 
Sp1 site near the transcriptional start 
sites (Ríus et al., 1998). An Alu se-
quence was found along the 5´ region of 
the ENG promoter. 741 bp fragment of 
ENG promoter mediates EC-specific 
transcription in cultured cells and also 
drives expression in murine vascular en-
dothelium (Ríus et al., 1998). Several 
potential binding sites for Ets, GATA, 
AP-2, NF-κB and Sp1 transcription fac-
tors are present within this promoter re-
gion. Studies on cultured cells indicate 
that Ets proteins regulate ENG promoter 
activity. Mutation in one of the EBSs 
dramatically reduced the promoter activ-
ity compared with that of the WT pro-
moter. Also a specific interaction of a 
member of the Ets family with this par-
ticular EBS was demonstrated by using 




Endothelin (ET-1) is critical for cardio-
vascular development in the embryo and 
for vascular homeostasis in the adult. It 
is expressed in ECs and in epithelial 
cells of the branchial arches during de-
velopment. Both mouse and human ET-1 
promoters have been isolated. The 5.9 
kbp 5´ flanking fragment of mouse ET-1 
directs gene expression to the endothe-
lial, epithelial and mesangial cells 
(Harats et al., 1995). Human ET-1 pro-
moter has a TATA box, and binding 
sites for AP-1 and GATA transcription 
factors are required for the expression of 
the ET-1 gene (Lee et al., 1999). Several 
members of the GATA family (GATA1, 
GATA2, and GATA3) and HIF-1α can 
transactivate the ET-1 gene (Kawana et 
al., 1995; Lee et al., 1991; Yamashita et 
al., 2001). Recently, a vascular endothe-
lial zinc finger 1 (Vezf1) transcription 
factor has been shown to transactivate 
the ET-1 promoter (Aitsebaomo et al., 
2001). Vezf1 expression is restricted to 
vascular endothelium and it is therefore 
an attractive candidate for a potential 
regulator of ET-1 gene expression in 
vivo (Aitsebaomo et al., 2001; Xiong et 
al., 1999).  
 
Intercellular adhesion molecule-2 
 
Intercellular adhesion molecule-2 
(ICAM2) is constitutively expressed on 
all vascular ECs and megakaryocytes as 
well as in some blood cells (de 
Fougerolles et al., 1991). A 0.33 kbp 5´ 
flanking region of the ICAM2 promoter 
confers EC-specific activity in vitro and 
in vivo (Cowan et al., 1996; Cowan et 
al., 1998). Sequence analysis revealed 
the presence of several DNA elements 
within this region; including an NF-κB 
and an Sp1 site, two GATA sites, four 
EBSs and an octamer, also present in the 
Tie1 promoter and Tie2 enhancer 
(Cowan et al., 1998). Results from muta-
tional and gel shift analyses demonstrate 
that the Sp1 site and the GATA sites 
function as positive regulatory elements 
in cultured ECs (Cowan et al., 1998). 
Transactivation studies indicate that 
GATA1 and GATA2 are able to activate 
the ICAM2 promoter (Cowan et al., 
1998). Furthermore, site-directed 
mutagenesis of the ICAM2 promoter im-
plicated that the octameric sequence, the 
NF-κB site and three consensus EBSs 
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are needed for basal activity (Cowan et 
al., 1998; McLaughlin et al., 1999). Two 
of these EBSs are involved in TNFα-
induced down-regulation of ICAM2 ex-
pression. Interestingly, TNFα stimula-
tion of cultured ECs reduces also Erg 
trancription factor expression, which is 
able to transactivate ICAM2 promoter 
(McLaughlin et al., 2001; McLaughlin et 
al., 1999). 
 
Endothelial nitric oxide synthase 
 
Endothelial nitric oxide synthase (eNos) 
is an enzyme responsible for generating 
nitric oxide and it is expressed predomi-
nantly in the endothelium. eNos has an 
important function in regulating vascular 
tone and remodeling (Huang et al., 1995; 
Rudic et al., 1998). The 1.6 kbp region 
of the human eNOS promoter targets re-
porter gene expression mainly to ECs 
both in vitro and in vivo (Guillot et al., 
1999; Guillot et al., 2000; Zhang et al., 
1995). However, this promoter drives 
reporter gene expression only to a sub-
population of ECs within the heart, 
skeletal muscle, brain and aorta, al-
though the endogenous gene is more 
broadly expressed, indicating that all the 
DNA elements needed to recapitulate 
eNOS gene expression are not present 
within the 1.6 kbp fragment (Guillot et 
al., 1999; Guillot et al., 2000). The 
eNOS promoter is TATA-less and trans-
fection studies in cultured cells by using 
various eNOS promoter constructs indi-
cate that Sp1 and GATA sites are impor-
tant for promoter activity (Zhang et al., 
1995). EMSA experiments indicate that 
Sp1 and GATA2 transcription factors 
are able to bind to these target sites in 
vitro (Zhang et al., 1995). 
2.2 Transcription factors regulating 
endothelial gene expression 
Characterization of the regulatory re-
gions of genes that are specifically ex-
pressed in ECs is a useful starting point 
for gaining information about the 
mechanisms that underlie endothelial 
differentiation and maturation. However, 
it is clear that the expression of even a 
single gene is regulated by several tran-
scription factors belonging to different 
families. Gene expression is regulated 
also temporally and spatially, depending 
on which transcription factors are pre-
sent at certain time and tissue. In addi-
tion to synthesis, the activity of tran-
scription factors may be controlled by 
modification, presence of the ligand or 
availability in the nucleus. As all of 
these regulatory events may participate 
in regulating the transcription of a single 
gene, it is evident that our knowledge 
about the expression of endothelial 
genes is still rather limited. However, 
comparison of transcription factor bind-
ing sites between different genes pre-
dominantly expressed in ECs indicate 
that EBSs and GATA sites are major 
regulators of promoter/enhancer activity 
in most of the cases. Therefore, the tran-
scription factors binding to these DNA 
elements are discussed below.  
2.2.1 Ets factors 
Ets transcription factor family includes 
over 50 members characterized by a 
conserved sequence of approximately 85 
aa named the Ets domain, which is re-
sponsible for DNA-binding (reviewed in 
Lelièvre et al., 2001). The Ets domain 
folds into a winged helix-turn-helix mo-
tif and binds to a consensus DNA se-
quence GGAA/T, named Ets binding site 
or EBS (Donaldson et al., 1994; Karim 
et al., 1990). The sequences flanking the 
EBS are variable and may affect the 
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binding specificity of Ets factors. Ets 
factors bind DNA generally as mono-
mers but they can also associate with 
other transcription factors bound to their 
cognate motifs in the vicinity of the EBS 
(Wasylyk et al., 1993). Ets proteins are 
implicated in the regulation of gene ex-
pression during many important biologi-
cal processes, such as cell growth, dif-
ferentiation and transformation. Most 
Ets proteins activate transcription except 
for Erf (Ets2 repressor protein), Net and 
Tel, which function as inhibitors (Lopez 
et al., 1999; Maira et al., 1996; Sgouras 
et al., 1995). The function of some Ets 
factors is regulated by phosphorylation 
of certain Thr or Ser residues as the re-
sult of MAPK or PI3K pathway stimula-
tion by activated oncogenes or receptor-
mediated tyrosine kinases (Yordy and 
Muise-Helmericks, 2000).  
 
EBSs are found in the regulatory regions 
of genes that encode growth factors, on-
coproteins, transcription factors and 
MMPs (reviewed in Lelièvre et al., 
2001). Ets1 is the founding member of 
the ETS family. Studies on cultured cells 
suggest that VEGFR1, Vegfr2, VE-
cadherin and VWF are directly regulated 
by Ets1 transcription factor (Dube et al., 
1999; Gory et al., 1998; Kappel et al., 
2000; Lelièvre et al., 2000; Schwachtgen 
et al., 1997; Wakiya et al., 1996). Ets1 is 
highly expressed by endothelial precur-
sors during vasculogenesis and in ECs 
during angiogenesis (reviewed in 
Lelièvre et al., 2001). However, Ets1 
expression is not restricted to the endo-
thelium since its mRNA is also found 
e.g. in the trophoblasts, somites and mi-
grating neural crest cells during embryo-
genesis and in stromal fibroblasts of in-
vasive tumors (Bolon et al., 1996; Fafeur 
et al., 1997; Luton et al., 1997; Wernert 
et al., 1994). Ets1 increases the mRNA 
levels of angiogenesis-related molecules 
such as MMPs, converting ECs to an 
active state (Oda et al., 1999). Overex-
pression of Ets1 in the ECs, but not in 
fibroblasts, decreased cell density at con-
fluence (Lelièvre et al., 2000). Loss of 
function experiments failed to address 
Ets1 role during vascular development, 
probably due to the redundant function 
of other members of this transcription 
factor family expressed in ECs (Barton 
et al., 1998).  
 
Ets2 has been shown to activate 
VEGFR1 and Vegfr2 promoters in vitro 
(Dube et al., 1999; Kappel et al., 2000; 
Wakiya et al., 1996). However, Ets2 is 
not expressed in ECs in vivo, indicating 
that it does not at least directly regulate 
EC-specific gene expression (Yamamoto 
et al., 1998). Ets2 expression is detected 
in many other cell types, in the develop-
ing limb buds and tail region during the 
early embryonic development 
(Maroulakou et al., 1994). Later, Ets2 is 
expressed in most organs including lung, 
skin, gut and brain (Kola et al., 1993; 
Maroulakou et al., 1994). Ets2 deficient 
mice die at E8.5 due to severe defects in 
extraembyonic tissues (Yamamoto et al., 
1998). If the extraembryonic defects are 
rescued by aggregation with tetraploid 
mouse embryos, Ets2 deficient mice are 
viable and show defects only in hair de-
velopment (Yamamoto et al., 1998). In-
terestingly, tumors grown in heterozy-
gous female mice carrying one defective 
Ets2 allele were one-half the size of tu-
mors grown in WT mice. These results 
suggest that Ets2 regulates tumor pro-
gression possibly via MMPs, and may 
thus regulate the expression of endothe-




Studies on cultured cells indicate that 
Erg regulates VEGFR1, VE-cadherin, 
VWF and ICAM-2 expression (Gory et 
al., 1998; McLaughlin et al., 1999; 
Schwachtgen et al., 1997; Wakiya et al., 
1996). During mouse embryogenesis, 
Erg is expressed in mesodermal tissues, 
including the endothelial, precartilagi-
nous and urogenital areas as well as in 
migrating neural crest cells (Vlaeminck-
Guillem et al., 2000). Decrease of Erg 
expression by antisense treatment results 
in decreased EC proliferation and tube 
formation, whereas injection of Xenopus 
Erg into Xenopus embryos was shown to 
lead to eye malformations and ectopic 
EC differentiation (Baltzinger et al., 
1999; McLaughlin et al., 2001). These 
results indicate that Erg is involved in 
blood vessel formation and it is therefore 
an attractive candidate for a direct tran-
scriptional regulator of endothelial genes 
in vivo. In addition, Erg regulates the 
transcription of genes encoding for ex-
tracellular proteolytic enzymes, and it 
inhibits the Ets2-mediated activation of 
the MMP3 promoter, indicating that it 
may modulate angiogenesis by several 
ways (Buttice et al., 1996).   
 
The other Ets factors that have been de-
tected so far in cultured ECs are Fli1, 
Nerf, ERM, ER81, and Tel. ERM and 
ER81 mRNAs have not been detected in 
ECs during mouse embryogenesis, indi-
cating that these transcription factors are 
not direct regulators of EC-specific tran-
scription of genes (Chotteau-Lelièvre et 
al., 1997). On the other hand, Fli1, Nerf 
(discussed in Results and Discussion 
section, pages 46-47), and Tel appear to 
have important functions during angio-
genesis. Fli1 is closely related to Erg in 
structure and it is expressed mainly in 
hematopoietic cells and ECs. Fli1 has an 
almost overlapping expression pattern 
with Erg during embryonic development 
(Mélet et al., 1996; Vlaeminck-Guillem 
et al., 2000). Fli1 gene disruption in 
mice leads to embryonic death at E12.5 
due to hemorrhages and impaired hema-
topoiesis (Hart et al., 2000; Spyropoulos 
et al., 2000). Fli1 is a target gene for 
Ets1 and overexpression of Fli1 activates 
the VE-cadherin promoter (Lelièvre et 
al., 2002). Interestingly, Tie2 levels in 
Fli1-deficient embryos were downregu-
lated in comparison  to their heterozy-
gous littermates, suggesting that Fli1 
regulates Tie2 expression in vivo (Hart et 
al., 2000). Tel is able to form 
homodimers, which is necessary for its 
activity (Lopez et al., 1999). In addition, 
Tel is able to bind Fli1 and to inhibit 
Fli1-mediated transactivation 
(Kwiatkowski et al., 1998). Targeted 
disruption of Tel results in defective an-
giogenesis in the embryonic yolk sac, in 
intra-embryonic apoptosis of mesen-
chymal and neural crest cells and in em-
bryonic death at E10.5-11.5 (Wang et 
al., 1997).  
2.2.2 GATA factors 
The GATA transcription factors play an 
important role in the regulation of a 
number of hematopoietic and endothelial 
genes. So far, six GATA transcription 
factors have been identified in verte-
brates. They recognize a consensus se-
quence motif, (G/A)GATA(A/T),  
through a conserved zinc finger DNA 
binding domain (Orkin, 1992). GATA1, 
GATA2 and GATA3 are prominently 
expressed in hematopoietic stem cells, 
while GATA4, GATA5, and GATA6 are 
expressed in mesodermally and endo-
dermally derived tissues. Gene inactiva-
tion studies of GATA factors failed to 
show a vascular phenotype in mice. Re-
sults indicated that GATA1, GATA2 and 
GATA3 are master regulators of hema-
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topoietic and lymphoid cell development 
(Ho et al., 1991; Joulin et al., 1991; Ko 
et al., 1991; Pevny et al., 1991; Tsai et 
al., 1994; Tsai et al., 1989). GATA4 null 
mice die around E8-E9 due to defects in 
heart development and ventral closure of 
the foregut (Kuo et al., 1997a; Molken-
tin et al., 1997). This phenotype results 
from defects in the folding of the em-
bryo needed for normal cardiac devel-
opment. GATA5 is largely dispensable 
for embryonic development, as the only 
phenotype resulting from targeted dis-
ruption of the GATA5 gene in mice is 
defective genitourinary tract develop-
ment in females (Molkentin et al., 
2000b). GATA6 deficient mice die early 
during development, at E6.5-E7.5 due to 
defects in visceral endoderm function 
(Koutsourakis et al., 1999; Morrisey et 
al., 1998). Though GATA factors are 
broadly expressed, it has been speculated 
that they regulate tissue-specific gene 
expression in multiple cell types through 
unique interactions with other transcrip-
tion factors (Molkentin et al., 2000a).  
 
GATA factors participate in the regula-
tion of PECAM-1, VWF, ICAM2, endo-
thelin-1, eNOS, and P-selectin promoter 
and Vegfr2 enhancer activities (Botella 
et al., 2000; Cowan et al., 1998; Gumina 
et al., 1997; Jahroudi and Lynch, 1994; 
Kappel et al., 2000; Kawana et al., 1995; 
Pan and McEver, 1993; Zhang et al., 
1995). In addition to hematopoietic cells, 
GATA2 is abundantly expressed in ECs, 
and it is therefore the best candidate for 
a GATA factor to regulate EC-specific 
gene expression (Dorfman et al., 1992; 
Orkin, 1992). Furthermore, recent stud-
ies indicate that GATA2 motif, together 
with EBSs located within a 3´ enhancer 
element of the Scl/Tal1 gene, target 
Scl/Tal1 transcription to hemangioblasts 
(Göttgens et al., 2002). Scl/Tal1 is a 
transcription factor that regulates  
VEGFR-2 expression (Kappel et al., 
2000). VEGFR-2 is the first endothelial 
marker to be expressed in mesodermal 
progenitor cells. Therefore, the charac-
terization of the upstream pathways 
regulating VEGFR-2 expression may 
provide information about heman-
gioblast commitment (Choi et al., 1998). 
Scl/Tal1 specifies vascular progenitors 
in zebrafish and its overexpression in-
creases the number of VEGFR-2 ex-
pressing endothelial precursor cells 
(Gering et al., 1998; Liao et al., 1998). 
Although yolk sac vascularization is de-
fective in Scl/Tal1 null mice, endothelial 
cell differentiation proceeds normally. 
Rescue of the hematopoietic defects by 
using the regulatory elements of GATA1 
transcription factor indicated that 
Scl/Tal-1 is dispensable for vascular cell 
specification but essential for angiogenic 
remodeling of the yolk sac capillary 
network into complex vitelline veins 
(Visvader et al., 1998).  
 
Taken together, it appears that none of 
the Ets or GATA factors characterized 
so far is the major common regulator of 
endothelial gene expression. Whether 
such general regulator for ECs exists, is 
not known yet. So far, only one tran-
scription factor, Vezf1, is known to be 
expressed in an EC-restricted manner 
(Xiong et al., 1999). However, the only 
downstream target identified for Vezf1 
is endothelin-1 (Aitsebaomo et al., 
2001). Another potential transcription 
factor regulating EC-specific gene ex-
pression is lung Kruppel-like factor 
(LKLF). It is predominantly expressed in 
lung ECs, but no changes in Tie1, Tie2 
or PDGF-B expression levels were seen 
in LKLF-deficient embryos, indicating 
that it does not regulate the expression of 
these genes (Kuo et al., 1997b). Also, it 
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is possible that ECs have specific co-
factors interacting with ubiquitous/semi-
restricted transcription factors, resulting 
in tissue-specific transcription of genes. 
However, comparison of the regulatory 
regions of EC-specific genes suggests 
that there are several different mecha-
nisms to target gene expression specifi-
cally to endothelial cells. Further studies 
are needed to reveal these complicated 
but fundamental issues. 
 
 
3 USE OF ENDOTHELIAL TARGETING ELEMENTS IN FUTURE GENE 
THERAPY
The regulatory regions driving gene ex-
pression specifically to the 
lymph/angiogenic ECs may have poten-
tial in the generation of targeting vectors 
for gene therapy of vascular diseases. As 
ECs line the lumen of blood vessels, 
they form a potentially useful target for 
gene therapy for several reasons. First, 
vascular endothelium has a major role in 
regulating important biological proc-
esses such as tumor angiogenesis. Sec-
ond, endothelium covers a large surface 
area in proximity to the circulation. 
Third, in tumors, ECs are less prone to 
developing genetic variants resistant to 
anti-angiogenic tumor therapy than tu-
mor cells (Kerbel, 1997). Furthermore, 
because angiogenesis does not occur in 
the adult except during times of wound 
healing, inflammation, ovulation and 
pregnancy, it is possible to develop 
therapies with minimal toxicities.  
 
The expression of at least most of the 
EC-specific genes is not ubiquitous in all 
types of endothelial cells, indicating that 
transcriptional control mechanisms dif-
fer between subpopulations of endothe-
lial cell lineage. Therefore, choice of the 
best promoter to be used in therapeutic 
stimulation or inhibition of angiogenesis 
depends on the target tissue. In fact, one 
of the bottlenecks in the identification of 
regulatory elements needed for targeting 
gene expression to ECs has been the lack 
of systematic dissection of the expres-
sion patterns driven by a certain regula-
tory region. Also, as most of the studies 
on EC-specific promoters have focused 
on a single promoter, comparison of the 
activities of different EC-specific pro-
moters for a certain application is diffi-
cult. However, recently studies compar-
ing the reporter gene activities driven by 
different endothelial regulatory regions 
have been published (He et al., 2001; 
Marchetti et al., 2002; Nicklin et al., 
2001). Furthermore, tumor vessels are 
heterogeneous and tumor angiogenesis 
results in differential activation of EC-
specific promoters (Minami et al., 2002). 
In some cases, the basic mechanism in-
volved in the interaction of tumor cells 
and endothelium may provide clues for 
choosing the best promoter. EC surface 
molecules may be involved in metastasis 
of different types of tumor cells. Unfor-
tunately, in many tumors the mechanism 
that facilitates the migration of circulat-
ing tumor cells into tissues is unre-
solved. Recently, use of the in vivo 
phage display method has demonstrated 
that tumor vascular ECs express a spe-
cific range of molecules (Pasqualini et 
al., 2000). This technology may provide 
tools for specific targeting of blood ves-
sels in primary tumors or metastases, as 
well as other disease-related endothelia. 
Several reports indicate that in some 
cancers, blood channels may be lined by 
cancer cells rather than by ECs, although 
these findings still need to be confirmed 
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(Pasqualini et al., 2002). If this kind of 
vascular mimicry exists in tumors, it 
may affect the efficacy of EC-targeted 
gene therapy. 
 
In addition to generating ways to target 
specific tissues and organs, there are a 
number of other open questions to be 
answered before successful gene therapy 
can be performed. These problems are 
related to the control of the efficiency 
and duration of gene expression, induc-
tion of immune reactions and possible 
cytotoxicity of vectors. Also, it has to be 
kept in mind that the promoter activity 
may change when the promoter is ligated 
into viral vectors often used to target 
ECs (Nicklin et al., 2001). Therefore, 
several ex vivo and in vivo experiments 
are needed to confirm the expression 
pattern driven by a certain regulatory 
region after ligation to a viral vector. 
Despite these concerns, studies on tumor 
cell lines and on mice indicate that ade-
novirus-based vectors containing either 
VEGFR1 or preproendothelin promoters 
may provide useful tools to target tumor 
endothelium (Bauerschmitz et al., 2002; 
Nicklin et al., 2001; Varda-Bloom et al., 
2001). Therefore, regulatory regions 
which target specifically ECs in vivo are 
not anymore the major limiting factor for 
the generation of therapeutic strategies 
to vascular diseases. However, genera-
tion of both efficient and safe endothelial 
gene targeting vectors for future gene 
therapies still remains both a challenge 
and an opportunity.   
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AIMS OF THE PRESENT STUDY 
 
This study was undertaken to obtain in-
formation about the transcriptional regu-
lation of Tie1 and Vegfr3 genes. Tie1 
promoter region targeting expression of 
the LacZ gene specifically to ECs in vivo 
had been previously identified, while 
nothing was known about the Vegfr3 
promoter. The specific aims of the study 
were: 
 
1. Characterization of DNA elements 
needed for Tie1 promoter activity 
and cell type specificity.  Our goal 
was to identify transcription factors 
that may regulate Tie1. To study the 
use of Tie1 promoter in future gene 
therapy to target expression of solu-
ble proteins into the blood circula-
tion, we generated transgenic mice 
expressing human growth hormone 
cDNA under the control of Tie1 
promoter. 
 
2. Generation of fluorescent Tie1 re-
porter mice to allow monitoring of 
vascular development in vivo and 
isolation of primary mouse endothe-
lial cells. Additionally, as the regula-
tory elements of EC-specific genes 
may have therapeutic applications, 
we also analyzed Tie1 transcription 
in tumor endothelium.  
 
3. Identification and characterization of 
the Vegfr3 promoter region. In par-
ticular, we were interested in finding 
out which region is required to drive 
gene expression specifically in lym-
phatic endothelium. As mutations in 
VEGFR3 gene have been linked to 
hereditary lymphedema, we wanted 
to characterize the genomic organi-
zation of the VEGFR3. 
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MATERIALS AND METHODS 
1. Characterization of DNA elements needed for Tie1 promoter activity and cell type 
specificity (I) 
 
To identify Tie1 RNA transcription ini-
tiation sites, RNase protection and 
primer extension assays were performed 
by analyzing RNA isolated from mouse 
embryos (E12) and adult kidneys.  It was 
known from a previous study that 0.8 
kbp Tie1 promoter confers EC-specific 
reporter gene expression in vivo 
(Korhonen, 1995). In order to study 
which of the conserved putative tran-
scription factor binding sites present in 
the Tie1 promoter are needed for its ac-
tivity and cell type specificity, the pro-
moter was cloned into a luciferase re-
porter vector. Progressive deletions and 
site-directed mutations were made to the 
promoter and the effect of these was 
studied in transfected cells by using a 
luciferase reporter assay. Both endothe-
lial and non-endothelial cells were used. 
Because a number of EBSs are con-
served between the mouse and human 
Tie1 promoters, the transactivation ca-
pacity of seven transcription factors of 
the Ets family was analyzed. To deter-
mine DNA sequences critical for EC-
specific expression of Tie1 in vivo, 
transgenic mice having a LacZ reporter 
driven by mutated Tie1 promoter frag-
ments were produced and analyzed for 
ß-galactosidase activity at E11.5. To 
study Tie1 promoter driven secretion of 
protein into the circulation, transgenic 
mice expressing the human growth hor-
mone cDNA under the control of Tie1 
promoter were generated. The level of 
hGH in the serum was determined by 
using a hGH immunoradiometric assay.  
 
2. Generation of fluorescent Tie1 reporter mice to allow monitoring of vascular de-
velopment and endothelial cell isolation (II) 
 
To produce transgenic reporter mice ex-
pressing green fluorescent protein in the 
vascular endothelium, EGFP or a fusion 
protein consisting of a Zeosin resistance 
marker and EGFP (ZEGFP) was ex-
pressed under the control of the Tie1 
promoter. The reporter gene expression 
in Tie1-Z/EGFP mouse lines was studied 
at E10.5 by fluorescence microscopy. 
Mouse lines expressing high levels of the 
transgene were studied further by analyz-
ing the transgene expression at several 
stages during embryogenesis and in 
adulthood. The Z/EGFP reporter expres-
sion pattern in Tie1-Z/EGFP mice was 
compared with the LacZ reporter expres-
sion pattern in Tie1-LacZ and 
Tie1+/LacZ mice, having the same pro-
moter fragment or the endogenous Tie1 
locus driving the LacZ expression, re-
spectively (Korhonen et al., 1995; Puri et 
al., 1995). In addition to fluorescence 
microscopy (Z/EGFP) and ß-
galactosidase staining (LacZ),  reporter 
gene expression in adult organs of Tie1-
Z/EGFP, Tie1-LacZ and Tie1+/LacZ 
mice was studied by Northern blot 
analysis and RT-PCR. To analyze Tie1 
expression in different types of vessels in 
adults, several organs from Tie1-LacZ 
and Tie1+/LacZ mice were studied fur-
ther after vascular perfusion with biotin-
labeled lectin and ß-galactosidase stain-
ing. As the Lycopersicon esculentum 
lectin binds to the surface of the ECs af-
ter intravenous injection, all blood ves-
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sels can be visualized. To study whether 
Tie1 is expressed in the lymphatic ves-
sels, the Tie1+/LacZ and Tie1-LacZ 
mice were mated with the K14-VEGFR-
3-Ig and K14-VEGF-C156S mice having 
lymphatic phenotypes (Mäkinen et al., 
2001a; Veikkola et al., 2001).  
 
To confirm the endothelial cell type spe-
cific expression of EGFP in Tie1-
Z/EGFP embryos, cells isolated at E9.5 
were allowed to attach on glass cover-
slips and were stained with antibodies 
against CD31 (MEC13.3, PharMingen, 
San Diego, CA), VEGFR-2 
(AVAS12α1, PharMingen) and VE-
cadherin (11D4.1, PharMingen). EGFP 
and CD31 expression was analyzed by 
flow cytometry. EGFP-positive cells 
were isolated by FACS. Cells from the 
positive pool were resuspended in cul-
ture medium, plated on gelatin and ex-
panded in culture. The expression of 
CD31, VEGFR-2 and VEGFR-3 (Kubo 
et al., 2000) was studied by immunofluo-
rescence stainings. EGFP, Tie1 and Tie2 
expression was followed also by North-
ern blot analysis. To produce endothelial 
cell lines, cells prepared from Tie1-
ZEGFP embryos at E12 were immortal-
ized by retroviral infection transfecting 
polyoma middle T-antigen and neomycin 
resistance selection marker into the cells. 
Selection with neomycin (800 µg/ml) 
alone and with various concentrations of 
Zeosin ranging from 100 µg/ml to 1.5 
mg/ml was started 72 h after the infec-
tion. Noninfected embryonic cells were 
used as controls. 
 
To analyze Tie1 promoter activation in 
pathological angiogenesis, Lewis lung 
carcinoma (LLC) cells were injected 
subcutaneously into the backs of Tie1-
Z/EGFP and Tie1-LacZ transgenic mice. 
For comparison, tumors grown in the 
Tie1+/LacZ mice were analyzed. Tu-
mors grown in Tie1-Z/EGFP mice were 
analyzed directly by fluorescence mi-
croscopy whereas tumors grown in Tie1-
LacZ transgenic and Tie1+/LacZ het-
erozygous mice were stained for ß-
galactosidase activity, followed by sec-
tioning and counterstaining with nuclear 
fast red. 
 
3. The genomic structure and regulatory region of VEGFR3 (III) 
 
To characterize the exon-intron bounda-
ries of VEGFR3, a genomic cosmid 
clone containing the entire sequence was 
subcloned and partially sequenced. Po-
lymorphic variation in the VEGFR3 gene 
was identified by resequencing more 
than 50 chromosomes and allele fre-
quencies were estimated from the se-
quence results. To identify the VEGFR3 
promoter region, the 5´ flanking regions 
of human and mouse VEGFR3 genes 
were isolated, sequenced and compared 
to each other. To analyze whether the 
upstream sequences of Vegfr3 confer 
promoter activity, a 3 kbp fragment 5´ to 
the first coding exon was cloned into a 
luciferase reporter vector. In addition, 
progressive 5´-deletions were made to 
the Vegfr3 promoter driving luciferase 
gene expression to find out critical se-
quences for its activity. Constructs were 
transfected in cultured endothelial and 
nonendothelial cells to study if Vegfr3 
promoter confers cell type specific tran-
scription. Cell extracts were assayed for 
luciferase activity. For in vivo analysis, 
transgenic mouse embryos having either 
the 3.6 kbp, 1.6 kbp or 0.8 kbp Vegfr3 
promoter fragment upstream of the LacZ 
reporter gene were generated. The em-
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bryos were genotyped by PCR analysis 
of amnion DNA and stained for ß-
galactosidase expression at E15.5. At 
that developmental stage, the lymphatic 
vessels are developing, while the skin is 
still permeable to the ß-galactosidase 
staining reagents.  
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RESULTS AND DISCUSSION 
1. DNA elements needed for the Tie1 promoter activity and cell type specificity  (I) 
 
RNase protection analysis from both 
embryonic and adult kidney RNAs using 
two riboprobes produced a doublet of 
bands having corresponding 5´ ends. The 
product of primer extension analysis had 
the corresponding 5´ end as the RNase 
protection product, indicating that Tie1 
promoter has a single major transcription 
start site. Tie1 promoter activity was 
studied in endothelial and nonendothelial 
cell lines and the results indicated that 
the activity of the promoter is relatively 
specific for ECs. Deletion of the 5´ end 
including the GT-repeat area and single 
EBS did not markedly change Tie1 pro-
moter activity, suggesting that these sites 
are dispensable for promoter activity. 
Studies of Tie1 promoter-LacZ trans-
genic embryos gave further support for 
this view, as some transgenic embryos 
showed reporter gene expression specifi-
cally in ECs when these sequences were 
deleted. In contrast, deletion of the 3´ 
end of the Tie1 promoter, including the 
transcription initiation site as well as mu-
tations made to the Ets doublet sites, to 
the AP-2 site or to the octamer sequence, 
reduced Tie1 promoter activity dramati-
cally in cultured cells. Interestingly, cer-
tain DNA elements present within the 
Tie1 promoter are found in regulatory 
regions of other mainly endothelial 
genes. Similar octameric sequences are 
found in the Tie2 enhancer and in the 
ICAM2 promoter (Cowan et al., 1998; 
Schlaeger et al., 1997). Whereas a muta-
tion destroying the Tie2 octamer mainly 
increased integration site dependency of 
the reporter construct, mutation of the 
octamer sequence present in the ICAM2 
promoter reduced reporter activity by 
70% in cultured ECs. Furthermore, 
transgenic embryos with mutated 3´ 
doublet EBS of the Tie1 promoter had 
strongly reduced reporter gene expres-
sion, confirming the critical role of these 
EBSs for Tie1 promoter activity. Ets fac-
tors are important regulators of Tie2 
gene as well. Deletion of the Tie2 enhan-
cer fragment containing solo and doublet 
EBSs completely abolished the in vivo 
activity of the enhancer (Schlaeger et al., 
1997). Also several other regulatory re-
gions of genes predominantly expressed 
in ECs have EBSs, suggesting that Ets 
transcription factors are important for 
EC-specific transcription (Table 2).  
 
Among the seven different members of 
Ets transcription factor family tested, 
NERF-2 showed the strongest (8.5 fold) 
transactivation of Tie1 promoter in vitro 
in an EBS-dependent manner. NERF-2 
is one of the three isoforms of NERF, 
which is a recently isolated member of 
the Ets factor family (Oettgen et al., 
1996). The other NERF isoform, NERF-
1A, was not able to transactivate Tie1 
promoter. Among the Ets family, NERF 
has the highest amino acid sequence 
homology to ELF-1. Interestingly, ELF-
1 is also able to transactivate Tie1 pro-
moter (Dube et al., 2001). NERF and 
ELF-1 are involved in the regulation of 
several T and B cell specific genes 
(Oettgen et al., 1996). Recent data indi-
cates that NERF-2 and ELF-1 are also 
able to transactivate Tie2 reporter con-
structs by 10 to 30 fold mainly via EBSs 
located in the proximal promoter (Dube 
et al., 1999) (Fig. 5). Both NERF-2 and 
ELF-1 are expressed in at least a subset 
of ECs. Therefore they are good candi-
dates for transcriptional regulators of Tie 
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genes in vivo (Dube et al., 1999; Dube et 
al., 2001). Recently, by using chicken 
(c) as a model, cNERF-2 expression has 
been reported to be high during the early 
development, particularly in the devel-
oping heart and limb (Gaspar et al., 
2002). In situ hybridization results indi-
cate that cNERF-2 is expressed pre-
dominantly in the developing neural tube 
and in the endothelium of large vessels, 
while ELF-1 is also highly expressed in 
the capillaries (Dube et al., 2001; Gaspar 
et al., 2002). Surprisingly, in contrast to 
cELF-1 and human NERF-2, cNERF-2 
does not transactivate Tie promoters, al-
though it is able to bind to the Tie1 and 
Tie2 EBSs. Cotransfection experiments 
of cNERF2 and cELF-1 with Tie1- and 
Tie2-reporter constructs demonstrate that 
cNERF-2 functions as a competitive in-
hibitor of cELF (Gaspar et al., 2002). 
These results suggest that a change in 
NERF-2 function from a negative to a 
positive regulator has occurred during 
evolution. 
 
The other Ets factors tested for their 
ability to transactivate Tie1 promoter 
were ETS-1, ETS-2, TEL, SAP-1 and 
ELK-1. Ets1, Ets2 and Tel have been 
shown to regulate angiogenesis (for dis-
cussion, see 2.2.1). SAP-1 and ELK1 
interact with the serum response factor. 
Our results indicate that ETS-1 and ETS-
2 are able to transactivate the Tie1 pro-
moter constructs maximally by three- to 
fourfold whereas the other Ets factors 
tested did not transactivate the Tie1 
promoter. None of these Ets factors 
could transactivate the Tie2 promoter or 
enhancer (Dube et al., 1999). Taken to-
gether, the results indicate that these 
transcription factors are not major regu-
lators of Tie genes. Recently, a DNA 
microarray analysis has been performed 
from a mouse brain EC line either over-
expressing Ets1 or not (Lelièvre et al., 
2002). Tie1 and Tie2, as well as Vegfr1 
and Vegfr2 gene expression profiles 
were similar in both cell lines, while VE-
cadherin and Ang2 expression levels 
were increased in Ets1 overexpressing 
ECs (Lelièvre et al., 2002; Lelièvre et 
al., 2000). In conclusion, although Ets1 
is highly expressed in ECs during vascu-
logenesis and angiogenesis, it is proba-
bly not the major regulator of EC pheno-
type. A summary of Ets factors transac-
tivating EC-specific genes is presented 
in Table 2. 
 
Table 2. Endothelial Ets target genes. 




















As angiogenesis is involved in many 
diseases, one goal in studying EC-
specific promoters is to define elements 
that might be useful for pro- or antian-
giogenic therapy. Transgenic mice ex-
pressing human growth hormone cDNA 
under the 0.8 kbp Tie1 promoter were 
generated and analyzed as a model of 
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Tie1 promoter driven secretion of pro-
tein into the circulation. High amounts 
of hGH  were detected in the circulation 
of transgenic mice and the hGH level 
correlated with the copy number of the 
transgene, indicating that the Tie1 pro-
moter may have potential for use in gene 
therapy. 
 
2. Generation of fluorescent Tie1 reporter mice to allow monitoring of vascular de-
velopment and endothelial cell isolation (II) 
 
Three founder lines showed fluorescence 
for EGFP and two for ZEGFP in the de-
veloping blood vessels of E10.5 em-
bryos. Intravital monitoring demon-
strated that the EGFP reporter recapitu-
lates the Tie1 expression pattern in the 
developing vasculature. The EGFP ex-
pression was not uniform throughout 
blood endothelia, as starting around 
midgestation, Tie1 promoter activity was 
stronger in the arteries than in the veins. 
Surprisingly, despite bright fluorescence 
seen in the vessels of Tie1-Z/EGFP 
transgenic embryos, no EGFP signal 
could be detected in most of the tissues 
in adult mice. However, several tissues 
from adult Tie1-LacZ transgenic and 
Tie1+/LacZ heterozygotic mice showed 
ß-galactosidase staining. As each EGFP 
protein molecule represents one fluoro-
phore, the fluorescence signal is not am-
plified as in the case of chromophore 
signal produced by the enzymatic ß-
galactosidase reporter. In most tissues 
analyzed, staining was weaker for the 
Tie1-LacZ transgene than for the 
Tie1+/lacZ knock-in, indicating that 
some regulatory elements needed for 
endogenous Tie1 expression in adult tis-
sues are missing from the 0.8 kbp Tie1 
promoter. It is unknown whether addi-
tional Tie1 enhancer elements are lo-
cated in the first intron as in the case of 
Tie2 and Vegfr2 genes. The results of 
Northern blot analysis and RT-PCR con-
firmed the lack of EGFP and LacZ ex-
pression in most tissues of transgenic 
mice, although endogenous Tie1 mRNA 
was detected in all tissues analyzed. Al-
together, our results indicate that the 
lack of fluorescence in adult Tie1-
Z/EGFP mice is due to the lack of re-
porter gene expression.  
 
Lectin perfused and ß-galactosidase 
stained skin from the ears of Tie1+/LacZ 
mice indicated Tie1 transcription mainly 
in the arterioles and in the capillaries, 
although very faint and scattered expres-
sion could be detected in large arteries 
and veins. Similar blood vascular ex-
pression pattern was seen in the Tie1-
LacZ transgenic mice, indicating that 
Tie1 promoter targets mainly arterioles 
and capillaries in adult mice. Further-
more, analysis of adult skin indicated 
that Tie1 transcription occurs also in the 
lymphatic endothelium. Similar reporter 
gene expression was seen in the lym-
phatic vessels of Tie1-LacZ and 
Tie1+/LacZ mice. The lymphatic nature 
of the stained vessels was confirmed by 
mating Tie1-LacZ transgenic and 
Tie1+/LacZ  heterozygous mice with 
transgenic mice having lymphatic hy-
poplasia or hyperplasia. The K14-
VEGFR-3-Ig adult mice lack lymphatic 
vessels of the skin, whereas the lym-
phatic vessels in the skin of the K14-
VEGF-C156S transgenic mice are hy-
perplastic (Mäkinen et al., 2001a; Veik-
kola et al., 2001). No blue vessels with-
out lectin staining were seen in the skin 
of Tie1-LacZ x K14-VEGFR-3-Ig mice, 
whereas in the Tie1+/LacZ x K14-
VEGF-C156S mice, the lectin-negative 
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and ß-galactosidase-positive vessels 
were dilated, confirming that Tie1 is 
transcribed in the lymphatic endothe-
lium. Lymphatic Tie1 transcription was 
not restricted to adult skin, as ß-
galactosidase expression was seen also in 
the lymphatic endothelium of the dia-
phragm and esophagus, in the lymphatic 
vessels on surface of the heart and small 
intestine as well as in mesenteric lym-
phatic vessels. Interestingly, comparison 
of wholemount ß-galactosidase-stained 
Tie1+/LacZ and VEGFR-3+/LacZ em-
bryos indicated that Tie1 is already ex-
pressed in the lymphatic endothelium 
during embryogenesis at E13.5. Further 
analyses are needed to characterize Tie1 
expression and its function in lymphatic 
endothelium in detail. Our preliminary 
results from Tie1 deficient embryos at 
E12.5 indicate that lymphatic vessels do 
form, indicating that Tie1 is not needed 
for lymphatic differentiation or initial 
formation of the lymphatic vasculature 
(K. Iljin, unpublished results). 
 
Flow cytometry using EGFP allowed the 
isolation of essentially pure Tie1 ex-
pressing endothelial cells from trans-
genic mouse embryos. All EGFP-
positive cells were also positive for 
CD31. CD31, VEGFR-2 and VEGFR-3 
were expressed in such cultures at pas-
sage 2, although their expression de-
creased upon repeated subculturing. The 
results of Northern blotting confirmed 
that the cells at passages 4 and 8 express 
EGFP, Tie1 and Tie2. The cellular mor-
phology was endothelial-like with a 
typical cobblestone morphology at con-
fluency. The cells retained EGFP posi-
tivity at least until passage 12. We were 
not able to produce stable endothelial 
cell cultures from the Tie1-ZEGFP em-
bryos by retroviral infection of polyoma 
middle T-antigen. Whether this was due 
to (1) reduced Tie1 promoter activity, (2) 
cytotoxicity of Z/EGFP, (3) environ-
mental changes caused by the death of 
surrounding cells or (4) nonoptimal cul-
ture conditions was not determined. 
However, EC-cultures have been made 
from differentiating Tie1-EGFP embry-
onic stem cells with integrated puromy-
cin resistance marker by using hygromy-
cin selection (Marchetti et al., 2002).  
Furthermore, as Tie1-Z/EGFP cells 
could be expanded in culture after FACS 
sorting, the first two possibilities are 
unlikely.  
 
Tie1 is expressed in ECs of certain hu-
man tumors, suggesting that Tie1 is 
needed for tumor angiogenesis (Brown 
et al., 2000; Hatva et al., 1996; Hatva et 
al., 1995; Kaipainen et al., 1994; Lin et 
al., 1999; Salven et al., 1996). As the 
regulatory regions driving gene expres-
sion specifically in the angiogenic ECs 
may have potential for use in gene ther-
apy, we analyzed the regulation of Tie1 
transcription during tumor neovasculari-
zation by transplanting Lewis lung car-
cinoma cells into Tie1-Z/EGFP, Tie1-
LacZ or Tie1+/LacZ mice. Our results 
indicate that although endogenous Tie1 
transcription is activated in tumor endo-
thelium, the mouse Tie1 promoter frag-
ment used did not contain the regulatory 
elements needed for the expression in 
tumor vasculature as no fluorescence or 
ß-galactosidase activity was seen in tu-
mors grown in Tie1-Z/EGFP or Tie1-






3. The genomic structure and promoter region of VEGFR3 (III) 
 
The coding sequence of the VEGFR3 
gene is organized into 31 exons that 
closely correspond to the genomic or-
ganization of the mouse Vegfr1 and hu-
man VEGFR2 genes (Kondo et al., 1998; 






Figure 8. Exon-intron structure of the human VEGFR3 and comparison of mouse and human 
VEGFR3 promoters. (A) The genomic structure of the human VEGFR3. The exons encoding for signal 
sequence (SS), Ig-homology domains (I-VII), transmembrane region (TM) and tyrosine kinase domains 
(TK I and TK II) are indicated.  (B) Schematic structure of the 5´ flanking regions of the human and mouse 
VEGFR3 genes. The putative transcription factor binding sites present within the homology regions 1 and 2 







All exon-intron boundaries were found 
to conform to the 5´-GT-AG-3´ splice 
site rule. The last two exons 30a and 30b 
of the VEGFR3 are alternatively spliced. 
In mice, only the longer isoform exists, 
and it has been reported that the shorter 
transcript in humans is the result of a 
retroviral insertion (Hughes, 2001; Paju-
sola et al., 1993). This insertion leads to 
diversity in the function of VEGFR-3, as 
the shorter form lacks three tyrosine 
residues that are important in down-
stream signaling (Fournier et al., 1995; 
Fournier et al., 1996). Resequencing of 
VEGFR3 identified 22 intragenic single 
nucleotide polymorphisms and an in-
tronic (CA)n repeat. The data concerning 
the exon-intron boundaries and poly-
morphisms of VEGFR3 is clinically im-
portant and useful, as missense muta-
tions in this gene have been linked to 
human hereditary lymphedema (Irrthum 
et al., 2000; Karkkainen et al., 2000). By 
using information about the VEGFR3 
genomic structure, rapid screening for 
mutations in VEGFR3-linked families of 
lymphedema or other inherited abnor-
malities of the lymphatic system is pos-
sible. 
 
The 5’ flanking regions of both human 
and mouse VEGFR3 genes were ana-
lyzed and two homology regions (HR1 
and HR2) showing 70% identity were 
identified (Fig. 8B). In the human pro-
moter, these elements were separated by 
an Alu repeat. Similar arrangements of 
Alu sequences are located 5´ to the pro-
moters of PECAM-1, VWF and ENG, 
and it has been suggested that a minimal 
promoter region would exist between the 
Alu sequence and the transcription ini-
tiation site (Almendro et al., 1996; As-
souline et al., 1988; Gumina et al., 1997; 
Ríus et al., 1998). No classical TATA or 
CAAT boxes were found in the VEGFR3 
genes. The 3.0 kbp flanking fragment of 
Vegfr3 demonstrated activity in cultured 
ECs but only minimal activity in kerati-
nocytes and fibroblasts. Deletion studies 
of the Vegfr3 promoter indicated that 
both homology elements were needed 
for activity. The 5´ homology element 
(HR1) had conserved putative binding 
sites for transcription factors conforming 
to the MEF-2, NF-1, AP-2, GATA and 
Ets families. Two EBSs were conserved 
in mouse and human promoters. The 3´ 
homology region contained multiple 
conserved binding sites for Sp1-like fac-
tors. Sp1 is a ubiquitous nuclear protein 
that can initiate transcription of TATA-
less genes. Further studies are needed to 
determine which consensus binding sites 
are critical for the Vegfr3 promoter ac-
tivity. 
 
To analyze whether the Vegfr3 regula-
tory region identified in vitro is also 
functional in vivo, transgenic mouse em-
bryos having either a 3.6 kbp HindIII 
/NotI, 1.6 kbp BsaI/NotI or 0.8 kbp 
SpeI/NotI promoter fragment driving the 
expression of a LacZ reporter gene were 
generated. The expression of the report-
ers in transgenic embryos was compared 
to that of Vegfr3+/LacZ mice at E15.5, 
when the expression pattern is restricted 
to lymphatic endothelium. The 3.6 and 
1.6 kbp Vegfr3 promoter fragments di-
rected weak lymphatic endothelial spe-
cific expression of the LacZ marker 
gene, whereas the 0.8 kbp promoter di-
rected reporter expression also in the 
blood vessels, indicating that regulatory 
elements needed to restrict gene expres-
sion to the lymphatic endothelium are 
located within the 0.8 kbp BsaI/SpeI 
Vegfr3 promoter fragment.  
 
The isolation of Vegfr3 promoter makes 
it possible to identify transcription fac-
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tors that contribute to lymphatic devel-
opment using techniques of mouse mo-
lecular genetics. However, Vegfr3 pro-
moter driven reporter gene expression 
appeared to be very integration-site de-
pendent. Therefore, for further studies, 
integration of the Vegfr3 promoter 
driven transgene to a predetermined site 
in the genome by homologous recombi-
nation might be a better approach to 
generate transgenic mice than random 
integration generally used in transgenic 
assays. Recently, several studies on en-
dothelial promoter-reporter gene con-
structs have successfully utilized this 
approach (Evans et al., 2000; Guillot et 
al., 2000). Also, isolation of putative ad-
ditional enhancer elements present else-
where in the Vegfr3 locus might increase 
the efficiency of Vegfr3 promoter driven 
transcription. Many tissue-specific genes 
have enhancer elements within the first 
two introns. Tie2 and Vegfr2 are exam-
ples of EC-specific genes whose activity 
is partly regulated by enhancers located 
in their first introns (Kappel et al., 1999; 
Schlaeger et al., 1997). Therefore, we 
started to analyze the first intron of 
Vegfr3 consisting of 14.8 kbp of ge-
nomic DNA. When compared with the 
human VEGFR3 first intronic sequence 
available, sequences were found to be 
70% homologous. Several short regions 
showing high homology were found, but 
so far, no additional enhancers could be 
identified. Another way to increase the 
efficacy of Vegfr3 promoter is to use 
“general” enhancers increasing promoter 
activity without losing its cellular speci-
ficity. This method has been used suc-
cessfully with the EC-specific VWF 
promoter, suggesting that in combination 
with the 1.6 kbp Vegfr3 promoter, effi-
cient targeting to lymphatic vasculature 
after midgestation  might be possible 
(Nettelbeck et al., 1998). 
 
4. Future prospects 
 
Although our results suggest that NERF-
2 regulates Tie1 transcription in vivo, the 
direct evidence is still missing. It is pos-
sible that the transactivation seen after 
overexpression of the transcription factor 
is the result of indirect regulation due to 
the altered gene expression profile over-
all. Also, it is not certain that the genes 
regulated by a factor that is highly over-
expressed as compared to its endogenous 
counterpart are true target genes. There-
fore, to determine if NERF-2 binds to 
the endogenous Tie1 promoter in physio-
logically relevant conditions, chromatin  
immunoprecipitation (ChIP) assay with  
cultured ECs could be performed. In this 
method, cells are briefly treated with 
formaldehyde to crosslink proteins to 
DNA. ChIP with an antibody against 
NERF-2, followed by PCR amplification 
using primers for the Tie1 promoter, 
could reveal whether the Tie1 promoter 
is a direct target of NERF-2 in vivo. To 
find out if NERF-2 regulates Tie1 tran-
scription during embryonic develop-
ment, fluorescent ECs could be isolated 
from Tie1-Z/EGFP embryos by FACS, 
followed by the ChIP assay. Further-
more, by using a modification of the 
ChIP method, it is possible to clone in-
dividual promoter or enhancer fragments 
bound by a specific transcription factor 
and to identify transcriptional regulatory 
networks (Weinmann and Farnham, 
2002). It would be interesting to study 
which regulatory elements are immuno-
precipitated with NERF-2 antibody, and 
compare those with the ones immuno-
precipitated with other antibodies, such 
as antibodies against Ets1.  
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Our results with both Tie1 and Vegfr3 
promoters indicate that some regulatory 
elements needed to recapitulate the en-
dogenous expression patterns of these 
genes are not present within the proxi-
mal promoter. To locate distant regula-
tory elements within the Tie1 and Vegfr3 
genes and surrounding chromosomal re-
gions, DNaseI sensitivity mapping or 
ChIP assays using antibodies specific for 
modified histones could be used (John-
son and Bresnick, 2002). Also, to find 
out which of the putative transcription 
factor binding sites present within HR1 
and HR2 of the Vegfr3 promoter are 
critical for promoter activity, site-
directed mutagenesis followed by analy-
sis of the mutant promoters in cultured 
cells could be performed.  The results 
obtained with other EC-specific genes 
suggest that Ets and GATA sites might 
be important for Vegfr3 promoter activ-
ity (for discussion, see Review of the 
literature; Regulation of EC-specific ex-
pression of genes and Results; DNA 
elements needed for the Tie1 promoter 
activity and cell type specificity). The 
putative MEF-2 binding site may also be 
a critical DNA element for Vegfr3 pro-
moter activity, as mice with a targeted 
mutagenesis of MEF-2C transcription 
factor have a similar phenotype to 
VEGFR-3 deficient mice (Dumont et al., 
1998; Lin et al., 1998). It would be cer-
tainly interesting to analyze the tran-
scription driven by mutant promoters 
also in transgenic mice, but without the 
use of additional enhancers, it would be 
very challenging due to the weak and 
integration site dependent Vegfr3 pro-




Although the formation of a functional 
vascular system is the result of a com-
plex process involving multiple cell 
types, the initial formation of a vascular 
network is accomplished by endothelial 
cells alone. Results obtained from stud-
ies on EC-specific promoters may pro-
vide insights into the fundamental 
mechanisms that mediate EC-specific 
transcription.  
 
A previous study had shown that the 0.8 
kbp fragment of the mouse Tie1 pro-
moter is sufficient to drive EC-specific 
transcription of the LacZ reporter gene in 
vivo. We determined the critical DNA 
elements present within this region for 
the Tie1 promoter activity. Our results 
indicate that Ets transcription factors are 
important regulators of Tie1 promoter 
activity. Ets factors control the expres-
sion of many other EC-specific genes as 
well, suggesting that these transcription 
factors have an important role in vascu-
lar development. Among the Ets factors 
tested, NERF-2 was the most potent ac-
tivator of the Tie1 promoter. However, 
further studies are needed to determine 
whether it is the major transcription fac-
tor regulating Tie1 expression during 
vascular development. We show that an 
octameric sequence and AP-2 site are 
also important for Tie1 promoter activ-
ity. Our results with the Tie1 promoter in 
combination with the results obtained 
from other EC-specific promoter studies 
indicate that the expression of EC-
specific genes requires the combinatorial 
function of many transcription factors. 
Although the transcriptional regulation 
of EC-specific genes has common char-
acteristics, it is evident that there are also 
differences, as the temporal and spatial 
expression pattern of different genes var-
ies. In order to understand the transcrip-
tional mechanisms underlying the speci-
fication of endothelial cells, precise de-
termination of the expression patterns of 
putative transcription factors and target 
genes needs to be accomplished. 
 
The promoter elements controlling endo-
thelial-specific gene expression are of 
special interest because they may be use-
ful in generating targeting vectors for 
gene therapy, directed to angiogenesis 
associated with tumor growth and metas-
tasis, or other disease processes involv-
ing the vascular system. Our results in-
dicate that the 0.8 kbp Tie1 promoter is 
not suitable for targeting tumor endothe-
lium but it can be used to drive the se-
cretion of soluble proteins to the blood 
circulation and may therefore have po-
tential for use in some applications of 
gene therapy. 
 
Large-scale isolation of primary endo-
thelial cells is of great interest for vascu-
lar gene profiling, for isolation of endo-
thelial cells for tissue engineering, and 
for proangiogenic treatment of patho-
logical conditions, such as tissue ische-
mia. Our results indicate that ECs can be 
isolated from Tie1-Z/EGFP transgenic 
mouse embryos by flow cytometry using 
EGFP. We believe that the Tie1-Z/EGFP 
mice could prove to be useful in angio-
genesis research, as they can be mated 
with other transgenic or knock-out mice 
and the endothelial cells from the double 
transgenics can be easily isolated for fur-
ther characterization in vitro.  
 
As VEGFR-3 is specifically expressed 
on the lymphatic endothelium, the regu-
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latory region of VEGFR3 may provide 
an important molecular tool in the at-
tempt to target the lymphatic system. In 
hereditary lymphedema with reduced 
VEGFR-3 signaling in heterozygous af-
fected individuals, genes that induce 
VEGFR-3 signaling specifically in the 
lymphatic endothelium might improve 
the growth and function of lymphatic 
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